{
"instance": {
"wst-20220630.htm": {
"axisCustom": 0,
"axisStandard": 27,
"contextCount": 350,
"dts": {
"calculationLink": {
"local": [
"wst-20220630_cal.xml"
]
},
"definitionLink": {
"local": [
"wst-20220630_def.xml"
]
},
"inline": {
"local": [
"wst-20220630.htm"
]
},
"labelLink": {
"local": [
"wst-20220630_lab.xml"
]
},
"presentationLink": {
"local": [
"wst-20220630_pre.xml"
]
},
"schema": {
"local": [
"wst-20220630.xsd"
],
"remote": [
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"http://www.xbrl.org/2006/ref-2006-02-27.xsd",
"http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
"https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
"https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
"https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
"https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
"https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
"https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
"https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
"https://xbrl.sec.gov/country/2022/country-2022.xsd",
"https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
"https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
]
}
},
"elementCount": 505,
"entityCount": 1,
"hidden": {
"http://xbrl.sec.gov/dei/2022": 5,
"total": 5
},
"keyCustom": 22,
"keyStandard": 280,
"memberCustom": 21,
"memberStandard": 61,
"nsprefix": "wst",
"nsuri": "http://www.westpharma.com/20220630",
"report": {
"R1": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:DocumentType",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "document",
"isDefault": "true",
"longName": "0001001 - Document - Cover Page",
"role": "http://www.westpharma.com/role/CoverPage",
"shortName": "Cover Page",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:DocumentType",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R10": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2104103 - Disclosure - Revenue",
"role": "http://www.westpharma.com/role/Revenue",
"shortName": "Revenue",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R11": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:EarningsPerShareTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2109104 - Disclosure - Net Income Per Share",
"role": "http://www.westpharma.com/role/NetIncomePerShare",
"shortName": "Net Income Per Share",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:EarningsPerShareTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R12": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:InventoryDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2113105 - Disclosure - Inventories",
"role": "http://www.westpharma.com/role/Inventories",
"shortName": "Inventories",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:InventoryDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R13": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:LesseeOperatingLeasesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2116106 - Disclosure - Leases",
"role": "http://www.westpharma.com/role/Leases",
"shortName": "Leases",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:LesseeOperatingLeasesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R14": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2122107 - Disclosure - Affiliated Companies",
"role": "http://www.westpharma.com/role/AffiliatedCompanies",
"shortName": "Affiliated Companies",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R15": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2124108 - Disclosure - Debt",
"role": "http://www.westpharma.com/role/Debt",
"shortName": "Debt",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R16": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2128109 - Disclosure - Derivative Financial Instruments",
"role": "http://www.westpharma.com/role/DerivativeFinancialInstruments",
"shortName": "Derivative Financial Instruments",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R17": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:FairValueDisclosuresTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2132110 - Disclosure - Fair Value Measurements",
"role": "http://www.westpharma.com/role/FairValueMeasurements",
"shortName": "Fair Value Measurements",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:FairValueDisclosuresTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R18": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2136111 - Disclosure - Accumulated Other Comprehensive Loss",
"role": "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLoss",
"shortName": "Accumulated Other Comprehensive Loss",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R19": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2140112 - Disclosure - Shareholders' Equity",
"role": "http://www.westpharma.com/role/ShareholdersEquity",
"shortName": "Shareholders' Equity",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R2": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i2a1a8b698be8432cb7ac8d6d468a8ec8_D20220401-20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "1001002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)",
"role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
"shortName": "CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i2a1a8b698be8432cb7ac8d6d468a8ec8_D20220401-20220630",
"decimals": "-5",
"lang": "en-US",
"name": "us-gaap:GrossProfit",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R20": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2144113 - Disclosure - Stock-Based Compensation",
"role": "http://www.westpharma.com/role/StockBasedCompensation",
"shortName": "Stock-Based Compensation",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R21": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2146114 - Disclosure - Benefit Plans",
"role": "http://www.westpharma.com/role/BenefitPlans",
"shortName": "Benefit Plans",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R22": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2150115 - Disclosure - Other (Income) Expense",
"role": "http://www.westpharma.com/role/OtherIncomeExpense",
"shortName": "Other (Income) Expense",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R23": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:IncomeTaxDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2156116 - Disclosure - Income Taxes",
"role": "http://www.westpharma.com/role/IncomeTaxes",
"shortName": "Income Taxes",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:IncomeTaxDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R24": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2158117 - Disclosure - Commitments and Contingencies",
"role": "http://www.westpharma.com/role/CommitmentsandContingencies",
"shortName": "Commitments and Contingencies",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R25": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SegmentReportingDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2159118 - Disclosure - Segment Information",
"role": "http://www.westpharma.com/role/SegmentInformation",
"shortName": "Segment Information",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SegmentReportingDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R26": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
"role": "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
"shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
"subGroupType": "policies",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R27": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2305301 - Disclosure - Revenue (Tables)",
"role": "http://www.westpharma.com/role/RevenueTables",
"shortName": "Revenue (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R28": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2310302 - Disclosure - Net Income Per Share (Tables)",
"role": "http://www.westpharma.com/role/NetIncomePerShareTables",
"shortName": "Net Income Per Share (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R29": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2314303 - Disclosure - Inventories (Tables)",
"role": "http://www.westpharma.com/role/InventoriesTables",
"shortName": "Inventories (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R3": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i2a1a8b698be8432cb7ac8d6d468a8ec8_D20220401-20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:NetIncomeLoss",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "1002003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)",
"role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED",
"shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i2a1a8b698be8432cb7ac8d6d468a8ec8_D20220401-20220630",
"decimals": "-5",
"lang": "en-US",
"name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R30": {
"firstAnchor": {
"ancestors": [
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:LeaseCostTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2317304 - Disclosure - Leases (Tables)",
"role": "http://www.westpharma.com/role/LeasesTables",
"shortName": "Leases (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:LeaseCostTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R31": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfDebtTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2325305 - Disclosure - Debt (Tables)",
"role": "http://www.westpharma.com/role/DebtTables",
"shortName": "Debt (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfDebtTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R32": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2329306 - Disclosure - Derivative Financial Instruments (Tables)",
"role": "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables",
"shortName": "Derivative Financial Instruments (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R33": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2333307 - Disclosure - Fair Value Measurements (Tables)",
"role": "http://www.westpharma.com/role/FairValueMeasurementsTables",
"shortName": "Fair Value Measurements (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R34": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2337308 - Disclosure - Accumulated Other Comprehensive Loss (Tables)",
"role": "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables",
"shortName": "Accumulated Other Comprehensive Loss (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R35": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2341309 - Disclosure - Shareholders' Equity (Tables)",
"role": "http://www.westpharma.com/role/ShareholdersEquityTables",
"shortName": "Shareholders' Equity (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R36": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2347310 - Disclosure - Benefit Plans (Tables)",
"role": "http://www.westpharma.com/role/BenefitPlansTables",
"shortName": "Benefit Plans (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R37": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2351311 - Disclosure - Other (Income) Expense (Tables)",
"role": "http://www.westpharma.com/role/OtherIncomeExpenseTables",
"shortName": "Other (Income) Expense (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R38": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2360312 - Disclosure - Segment Information (Tables)",
"role": "http://www.westpharma.com/role/SegmentInformationTables",
"shortName": "Segment Information (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R39": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"td",
"tr",
"table",
"div",
"us-gaap:DisaggregationOfRevenueTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i6ea09ac30c2e4b939a03cd7b3e78b2ae_D20220401-20220630",
"decimals": "2",
"first": true,
"lang": "en-US",
"name": "us-gaap:ConcentrationRiskPercentage1",
"reportCount": 1,
"unique": true,
"unitRef": "number",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2406401 - Disclosure - Revenue - Revenue Recognition (Details)",
"role": "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails",
"shortName": "Revenue - Revenue Recognition (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"td",
"tr",
"table",
"div",
"us-gaap:DisaggregationOfRevenueTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i6ea09ac30c2e4b939a03cd7b3e78b2ae_D20220401-20220630",
"decimals": "2",
"first": true,
"lang": "en-US",
"name": "us-gaap:ConcentrationRiskPercentage1",
"reportCount": 1,
"unique": true,
"unitRef": "number",
"xsiNil": "false"
}
},
"R4": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i2a1a8b698be8432cb7ac8d6d468a8ec8_D20220401-20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical)",
"role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical",
"shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical)",
"subGroupType": "parenthetical",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i2a1a8b698be8432cb7ac8d6d468a8ec8_D20220401-20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R40": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i9228f5d0477740779a6644107e8c6524_I20211231",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:ContractWithCustomerAssetNet",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2407402 - Disclosure - Revenue - Contracts and Liabilities (Details)",
"role": "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails",
"shortName": "Revenue - Contracts and Liabilities (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i9228f5d0477740779a6644107e8c6524_I20211231",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:ContractWithCustomerAssetNet",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R41": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2408403 - Disclosure - Revenue - Narrative (Details)",
"role": "http://www.westpharma.com/role/RevenueNarrativeDetails",
"shortName": "Revenue - Narrative (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R42": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i2a1a8b698be8432cb7ac8d6d468a8ec8_D20220401-20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:NetIncomeLoss",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2411404 - Disclosure - Net Income Per Share - Summary of Net Income Per Share (Details)",
"role": "http://www.westpharma.com/role/NetIncomePerShareSummaryofNetIncomePerShareDetails",
"shortName": "Net Income Per Share - Summary of Net Income Per Share (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i2a1a8b698be8432cb7ac8d6d468a8ec8_D20220401-20220630",
"decimals": "-5",
"lang": "en-US",
"name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
}
},
"R43": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i2a1a8b698be8432cb7ac8d6d468a8ec8_D20220401-20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2412405 - Disclosure - Net Income Per Share - Narrative (Details)",
"role": "http://www.westpharma.com/role/NetIncomePerShareNarrativeDetails",
"shortName": "Net Income Per Share - Narrative (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i2a1a8b698be8432cb7ac8d6d468a8ec8_D20220401-20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
}
},
"R44": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "ifccb43af47e74519bb567ed133ce9194_I20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:InventoryRawMaterialsNetOfReserves",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2415406 - Disclosure - Inventories (Details)",
"role": "http://www.westpharma.com/role/InventoriesDetails",
"shortName": "Inventories (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "ifccb43af47e74519bb567ed133ce9194_I20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:InventoryRawMaterialsNetOfReserves",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R45": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"us-gaap:LeaseCostTableTextBlock",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i2a1a8b698be8432cb7ac8d6d468a8ec8_D20220401-20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:OperatingLeaseCost",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2418407 - Disclosure - Leases - Lease Cost (Details)",
"role": "http://www.westpharma.com/role/LeasesLeaseCostDetails",
"shortName": "Leases - Lease Cost (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"us-gaap:LeaseCostTableTextBlock",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i2a1a8b698be8432cb7ac8d6d468a8ec8_D20220401-20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:OperatingLeaseCost",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R46": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"wst:LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i2a1a8b698be8432cb7ac8d6d468a8ec8_D20220401-20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:OperatingLeasePayments",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2419408 - Disclosure - Leases - Lease Cash Flow and Supplemental Information (Details)",
"role": "http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails",
"shortName": "Leases - Lease Cash Flow and Supplemental Information (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"wst:LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i2a1a8b698be8432cb7ac8d6d468a8ec8_D20220401-20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:OperatingLeasePayments",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R47": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "ifccb43af47e74519bb567ed133ce9194_I20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2420409 - Disclosure - Leases - Lease Weighted Average (Details)",
"role": "http://www.westpharma.com/role/LeasesLeaseWeightedAverageDetails",
"shortName": "Leases - Lease Weighted Average (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "ifccb43af47e74519bb567ed133ce9194_I20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R48": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "ifccb43af47e74519bb567ed133ce9194_I20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2421410 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)",
"role": "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails",
"shortName": "Leases - Maturities of Operating Lease Liabilities (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "ifccb43af47e74519bb567ed133ce9194_I20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R49": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "ifccb43af47e74519bb567ed133ce9194_I20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:EquityMethodInvestments",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2423411 - Disclosure - Affiliated Companies (Details)",
"role": "http://www.westpharma.com/role/AffiliatedCompaniesDetails",
"shortName": "Affiliated Companies (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i9228f5d0477740779a6644107e8c6524_I20211231",
"decimals": "-5",
"lang": "en-US",
"name": "us-gaap:EquityMethodInvestments",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R5": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "ifccb43af47e74519bb567ed133ce9194_I20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "1004005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)",
"role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED",
"shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "ifccb43af47e74519bb567ed133ce9194_I20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R50": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfDebtTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "ifccb43af47e74519bb567ed133ce9194_I20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtInstrumentCarryingAmount",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2426412 - Disclosure - Debt - Long-term Debt (Details)",
"role": "http://www.westpharma.com/role/DebtLongtermDebtDetails",
"shortName": "Debt - Long-term Debt (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfDebtTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "ifccb43af47e74519bb567ed133ce9194_I20220630",
"decimals": "-5",
"lang": "en-US",
"name": "us-gaap:UnamortizedDebtIssuanceExpense",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R51": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfDebtTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "ifccb43af47e74519bb567ed133ce9194_I20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtInstrumentCarryingAmount",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2427413 - Disclosure - Debt - Narrative (Details)",
"role": "http://www.westpharma.com/role/DebtNarrativeDetails",
"shortName": "Debt - Narrative (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i2457bbd54c7b450f9766ffb7835b802c_I20220331",
"decimals": "-5",
"lang": "en-US",
"name": "us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R52": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "ie1b2556a75a84b07bb8b03078999dd7a_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DerivativeTermOfContract",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2430414 - Disclosure - Derivative Financial Instruments - Foreign Exchange Rate and Commodity Price Risk (Details)",
"role": "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails",
"shortName": "Derivative Financial Instruments - Foreign Exchange Rate and Commodity Price Risk (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "ie1b2556a75a84b07bb8b03078999dd7a_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DerivativeTermOfContract",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R53": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i2a1a8b698be8432cb7ac8d6d468a8ec8_D20220401-20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2431415 - Disclosure - Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details)",
"role": "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails",
"shortName": "Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i2a1a8b698be8432cb7ac8d6d468a8ec8_D20220401-20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R54": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "ifccb43af47e74519bb567ed133ce9194_I20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:DeferredCompensationPlanAssets",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2434416 - Disclosure - Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details)",
"role": "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails",
"shortName": "Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "ifccb43af47e74519bb567ed133ce9194_I20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:DeferredCompensationPlanAssets",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R55": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "ifccb43af47e74519bb567ed133ce9194_I20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:LongTermDebtFairValue",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2435417 - Disclosure - Fair Value Measurement - Other Financial Instruments (Details)",
"role": "http://www.westpharma.com/role/FairValueMeasurementOtherFinancialInstrumentsDetails",
"shortName": "Fair Value Measurement - Other Financial Instruments (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "ifccb43af47e74519bb567ed133ce9194_I20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:LongTermDebtFairValue",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R56": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "ib74283a08c814d13848d26e8c2d089bf_I20220331",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:StockholdersEquity",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2438418 - Disclosure - Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details)",
"role": "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails",
"shortName": "Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": "-5",
"lang": "en-US",
"name": "us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R57": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i2a1a8b698be8432cb7ac8d6d468a8ec8_D20220401-20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:CostOfGoodsAndServicesSold",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2439419 - Disclosure - Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details)",
"role": "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails",
"shortName": "Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i41d4cd8ef84542598067f4c8e799dba3_D20220401-20220630",
"decimals": "-5",
"lang": "en-US",
"name": "us-gaap:NetIncomeLoss",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R58": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i9228f5d0477740779a6644107e8c6524_I20211231",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:CommonStockSharesIssued",
"reportCount": 1,
"unitRef": "shares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2442420 - Disclosure - Shareholder's Equity - Change in Shareholders' Equity (Details)",
"role": "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails",
"shortName": "Shareholder's Equity - Change in Shareholders' Equity (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i2a1a8b698be8432cb7ac8d6d468a8ec8_D20220401-20220630",
"decimals": "-5",
"lang": "en-US",
"name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R59": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i2a1a8b698be8432cb7ac8d6d468a8ec8_D20220401-20220630",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:CommonStockDividendsPerShareDeclared",
"reportCount": 1,
"unique": true,
"unitRef": "usdPerShare",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2443421 - Disclosure - Shareholder's Equity - Supplemental Equity Information (Details)",
"role": "http://www.westpharma.com/role/ShareholdersEquitySupplementalEquityInformationDetails",
"shortName": "Shareholder's Equity - Supplemental Equity Information (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i2a1a8b698be8432cb7ac8d6d468a8ec8_D20220401-20220630",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:CommonStockDividendsPerShareDeclared",
"reportCount": 1,
"unique": true,
"unitRef": "usdPerShare",
"xsiNil": "false"
}
},
"R6": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "ifccb43af47e74519bb567ed133ce9194_I20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:PreferredStockSharesAuthorized",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "1005006 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)",
"role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical",
"shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)",
"subGroupType": "parenthetical",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "ifccb43af47e74519bb567ed133ce9194_I20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:PreferredStockSharesAuthorized",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
}
},
"R60": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "ifccb43af47e74519bb567ed133ce9194_I20220630",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
"reportCount": 1,
"unitRef": "shares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2445422 - Disclosure - Stock-Based Compensation (Details)",
"role": "http://www.westpharma.com/role/StockBasedCompensationDetails",
"shortName": "Stock-Based Compensation (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": "INF",
"lang": "en-US",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
}
},
"R61": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i2a1a8b698be8432cb7ac8d6d468a8ec8_D20220401-20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:DefinedBenefitPlanServiceCost",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2448423 - Disclosure - Benefit Plans - Schedule of Components of Net Periodic Benefit Cost (Details)",
"role": "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails",
"shortName": "Benefit Plans - Schedule of Components of Net Periodic Benefit Cost (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i2a1a8b698be8432cb7ac8d6d468a8ec8_D20220401-20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:DefinedBenefitPlanServiceCost",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R62": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i2a1a8b698be8432cb7ac8d6d468a8ec8_D20220401-20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2449424 - Disclosure - Benefit Plans - Narrative (Details)",
"role": "http://www.westpharma.com/role/BenefitPlansNarrativeDetails",
"shortName": "Benefit Plans - Narrative (Details)",
"subGroupType": "details",
"uniqueAnchor": null
},
"R63": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i2a1a8b698be8432cb7ac8d6d468a8ec8_D20220401-20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2452425 - Disclosure - Other (Income) Expense - Summary (Details)",
"role": "http://www.westpharma.com/role/OtherIncomeExpenseSummaryDetails",
"shortName": "Other (Income) Expense - Summary (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i2a1a8b698be8432cb7ac8d6d468a8ec8_D20220401-20220630",
"decimals": "-5",
"lang": "en-US",
"name": "us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R64": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i3308c48ef02741ada5451721e3f61794_D20200701-20200731",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "wst:RestructuringAndRelatedActivitiesPeriodOfImplementation",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2453426 - Disclosure - Other (Income) Expense - Narrative (Details)",
"role": "http://www.westpharma.com/role/OtherIncomeExpenseNarrativeDetails",
"shortName": "Other (Income) Expense - Narrative (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i3308c48ef02741ada5451721e3f61794_D20200701-20200731",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "wst:RestructuringAndRelatedActivitiesPeriodOfImplementation",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R65": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i2a1a8b698be8432cb7ac8d6d468a8ec8_D20220401-20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2454427 - Disclosure - Other (Income) Expense - Restructuring and Related Charges (Details)",
"role": "http://www.westpharma.com/role/OtherIncomeExpenseRestructuringandRelatedChargesDetails",
"shortName": "Other (Income) Expense - Restructuring and Related Charges (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i1671bc32796541d3818206d0bba379fe_I20211231",
"decimals": "-5",
"lang": "en-US",
"name": "us-gaap:RestructuringReserve",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R66": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2455428 - Disclosure - Other (Income) Expense - Other Items (Details)",
"role": "http://www.westpharma.com/role/OtherIncomeExpenseOtherItemsDetails",
"shortName": "Other (Income) Expense - Other Items (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R67": {
"firstAnchor": {
"ancestors": [
"span",
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i2a1a8b698be8432cb7ac8d6d468a8ec8_D20220401-20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:IncomeTaxExpenseBenefit",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2457429 - Disclosure - Income Taxes (Details)",
"role": "http://www.westpharma.com/role/IncomeTaxesDetails",
"shortName": "Income Taxes (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "i2a1a8b698be8432cb7ac8d6d468a8ec8_D20220401-20220630",
"decimals": "3",
"lang": "en-US",
"name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
"reportCount": 1,
"unique": true,
"unitRef": "number",
"xsiNil": "false"
}
},
"R68": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:NumberOfReportableSegments",
"reportCount": 1,
"unique": true,
"unitRef": "segment",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2461430 - Disclosure - Segment Information (Details)",
"role": "http://www.westpharma.com/role/SegmentInformationDetails",
"shortName": "Segment Information (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:NumberOfReportableSegments",
"reportCount": 1,
"unique": true,
"unitRef": "segment",
"xsiNil": "false"
}
},
"R7": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:NetIncomeLoss",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)",
"role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
"shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": "-5",
"lang": "en-US",
"name": "us-gaap:Depreciation",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R8": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SignificantAccountingPoliciesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
"role": "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
"shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SignificantAccountingPoliciesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R9": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2103102 - Disclosure - New Accounting Standards",
"role": "http://www.westpharma.com/role/NewAccountingStandards",
"shortName": "New Accounting Standards",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "wst-20220630.htm",
"contextRef": "id6a4ce6563194e9cb351b7ca32adab93_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
}
},
"segmentCount": 82,
"tag": {
"country_US": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "UNITED STATES",
"terseLabel": "U.S. plans"
}
}
},
"localname": "US",
"nsuri": "http://xbrl.sec.gov/country/2022",
"presentation": [
"http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"
],
"xbrltype": "domainItemType"
},
"currency_AllCurrenciesDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "All Currencies [Domain]",
"terseLabel": "All Currencies [Domain]"
}
}
},
"localname": "AllCurrenciesDomain",
"nsuri": "http://xbrl.sec.gov/currency/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"
],
"xbrltype": "domainItemType"
},
"currency_JPY": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Japan, Yen",
"terseLabel": "JPY"
}
}
},
"localname": "JPY",
"nsuri": "http://xbrl.sec.gov/currency/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"
],
"xbrltype": "domainItemType"
},
"currency_SGD": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Singapore, Dollars",
"terseLabel": "SGD"
}
}
},
"localname": "SGD",
"nsuri": "http://xbrl.sec.gov/currency/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"
],
"xbrltype": "domainItemType"
},
"currency_USD": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "United States of America, Dollars",
"terseLabel": "USD"
}
}
},
"localname": "USD",
"nsuri": "http://xbrl.sec.gov/currency/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"
],
"xbrltype": "domainItemType"
},
"dei_AmendmentFlag": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
"label": "Amendment Flag",
"terseLabel": "Amendment Flag"
}
}
},
"localname": "AmendmentFlag",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.westpharma.com/role/CoverPage"
],
"xbrltype": "booleanItemType"
},
"dei_CityAreaCode": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Area code of city",
"label": "City Area Code",
"terseLabel": "City Area Code"
}
}
},
"localname": "CityAreaCode",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.westpharma.com/role/CoverPage"
],
"xbrltype": "normalizedStringItemType"
},
"dei_CoverAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Cover page.",
"label": "Cover [Abstract]"
}
}
},
"localname": "CoverAbstract",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"xbrltype": "stringItemType"
},
"dei_CurrentFiscalYearEndDate": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "End date of current fiscal year in the format --MM-DD.",
"label": "Current Fiscal Year End Date",
"terseLabel": "Current Fiscal Year End Date"
}
}
},
"localname": "CurrentFiscalYearEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.westpharma.com/role/CoverPage"
],
"xbrltype": "gMonthDayItemType"
},
"dei_DocumentFiscalPeriodFocus": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
"label": "Document Fiscal Period Focus",
"terseLabel": "Document Fiscal Period Focus"
}
}
},
"localname": "DocumentFiscalPeriodFocus",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.westpharma.com/role/CoverPage"
],
"xbrltype": "fiscalPeriodItemType"
},
"dei_DocumentFiscalYearFocus": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
"label": "Document Fiscal Year Focus",
"terseLabel": "Document Fiscal Year Focus"
}
}
},
"localname": "DocumentFiscalYearFocus",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.westpharma.com/role/CoverPage"
],
"xbrltype": "gYearItemType"
},
"dei_DocumentPeriodEndDate": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.",
"label": "Document Period End Date",
"terseLabel": "Document Period End Date"
}
}
},
"localname": "DocumentPeriodEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.westpharma.com/role/CoverPage"
],
"xbrltype": "dateItemType"
},
"dei_DocumentQuarterlyReport": {
"auth_ref": [
"r716"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true only for a form used as an quarterly report.",
"label": "Document Quarterly Report",
"terseLabel": "Document Quarterly Report"
}
}
},
"localname": "DocumentQuarterlyReport",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.westpharma.com/role/CoverPage"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentTransitionReport": {
"auth_ref": [
"r717"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true only for a form used as a transition report.",
"label": "Document Transition Report",
"terseLabel": "Document Transition Report"
}
}
},
"localname": "DocumentTransitionReport",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.westpharma.com/role/CoverPage"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentType": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
"label": "Document Type",
"terseLabel": "Document Type"
}
}
},
"localname": "DocumentType",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.westpharma.com/role/CoverPage"
],
"xbrltype": "submissionTypeItemType"
},
"dei_EntityAddressAddressLine1": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Address Line 1 such as Attn, Building Name, Street Name",
"label": "Entity Address, Address Line One",
"terseLabel": "Entity Address, Address Line One"
}
}
},
"localname": "EntityAddressAddressLine1",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.westpharma.com/role/CoverPage"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressCityOrTown": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the City or Town",
"label": "Entity Address, City or Town",
"terseLabel": "Entity Address, City or Town"
}
}
},
"localname": "EntityAddressCityOrTown",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.westpharma.com/role/CoverPage"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressPostalZipCode": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Code for the postal or zip code",
"label": "Entity Address, Postal Zip Code",
"terseLabel": "Entity Address, Postal Zip Code"
}
}
},
"localname": "EntityAddressPostalZipCode",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.westpharma.com/role/CoverPage"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressStateOrProvince": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the state or province.",
"label": "Entity Address, State or Province",
"terseLabel": "Entity Address, State or Province"
}
}
},
"localname": "EntityAddressStateOrProvince",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.westpharma.com/role/CoverPage"
],
"xbrltype": "stateOrProvinceItemType"
},
"dei_EntityCentralIndexKey": {
"auth_ref": [
"r714"
],
"lang": {
"en-us": {
"role": {
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
"label": "Entity Central Index Key",
"terseLabel": "Entity Central Index Key"
}
}
},
"localname": "EntityCentralIndexKey",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.westpharma.com/role/CoverPage"
],
"xbrltype": "centralIndexKeyItemType"
},
"dei_EntityCommonStockSharesOutstanding": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
"label": "Entity Common Stock, Shares Outstanding",
"terseLabel": "Entity Common Stock, Shares Outstanding"
}
}
},
"localname": "EntityCommonStockSharesOutstanding",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.westpharma.com/role/CoverPage"
],
"xbrltype": "sharesItemType"
},
"dei_EntityCurrentReportingStatus": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
"label": "Entity Current Reporting Status",
"terseLabel": "Entity Current Reporting Status"
}
}
},
"localname": "EntityCurrentReportingStatus",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.westpharma.com/role/CoverPage"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityEmergingGrowthCompany": {
"auth_ref": [
"r714"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate if registrant meets the emerging growth company criteria.",
"label": "Entity Emerging Growth Company",
"terseLabel": "Entity Emerging Growth Company"
}
}
},
"localname": "EntityEmergingGrowthCompany",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.westpharma.com/role/CoverPage"
],
"xbrltype": "booleanItemType"
},
"dei_EntityFileNumber": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
"label": "Entity File Number",
"terseLabel": "Entity File Number"
}
}
},
"localname": "EntityFileNumber",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.westpharma.com/role/CoverPage"
],
"xbrltype": "fileNumberItemType"
},
"dei_EntityFilerCategory": {
"auth_ref": [
"r714"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
"label": "Entity Filer Category",
"terseLabel": "Entity Filer Category"
}
}
},
"localname": "EntityFilerCategory",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.westpharma.com/role/CoverPage"
],
"xbrltype": "filerCategoryItemType"
},
"dei_EntityIncorporationStateCountryCode": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Two-character EDGAR code representing the state or country of incorporation.",
"label": "Entity Incorporation, State or Country Code",
"terseLabel": "Entity Incorporation, State or Country Code"
}
}
},
"localname": "EntityIncorporationStateCountryCode",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.westpharma.com/role/CoverPage"
],
"xbrltype": "edgarStateCountryItemType"
},
"dei_EntityInteractiveDataCurrent": {
"auth_ref": [
"r718"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
"label": "Entity Interactive Data Current",
"terseLabel": "Entity Interactive Data Current"
}
}
},
"localname": "EntityInteractiveDataCurrent",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.westpharma.com/role/CoverPage"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityRegistrantName": {
"auth_ref": [
"r714"
],
"lang": {
"en-us": {
"role": {
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
"label": "Entity Registrant Name",
"terseLabel": "Entity Registrant Name"
}
}
},
"localname": "EntityRegistrantName",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.westpharma.com/role/CoverPage"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityShellCompany": {
"auth_ref": [
"r714"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
"label": "Entity Shell Company",
"terseLabel": "Entity Shell Company"
}
}
},
"localname": "EntityShellCompany",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.westpharma.com/role/CoverPage"
],
"xbrltype": "booleanItemType"
},
"dei_EntitySmallBusiness": {
"auth_ref": [
"r714"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
"label": "Entity Small Business",
"terseLabel": "Entity Small Business"
}
}
},
"localname": "EntitySmallBusiness",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.westpharma.com/role/CoverPage"
],
"xbrltype": "booleanItemType"
},
"dei_EntityTaxIdentificationNumber": {
"auth_ref": [
"r714"
],
"lang": {
"en-us": {
"role": {
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
"label": "Entity Tax Identification Number",
"terseLabel": "Entity Tax Identification Number"
}
}
},
"localname": "EntityTaxIdentificationNumber",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.westpharma.com/role/CoverPage"
],
"xbrltype": "employerIdItemType"
},
"dei_LocalPhoneNumber": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Local phone number for entity.",
"label": "Local Phone Number",
"terseLabel": "Local Phone Number"
}
}
},
"localname": "LocalPhoneNumber",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.westpharma.com/role/CoverPage"
],
"xbrltype": "normalizedStringItemType"
},
"dei_Security12bTitle": {
"auth_ref": [
"r713"
],
"lang": {
"en-us": {
"role": {
"documentation": "Title of a 12(b) registered security.",
"label": "Title of 12(b) Security",
"terseLabel": "Title of each class"
}
}
},
"localname": "Security12bTitle",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.westpharma.com/role/CoverPage"
],
"xbrltype": "securityTitleItemType"
},
"dei_SecurityExchangeName": {
"auth_ref": [
"r715"
],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the Exchange on which a security is registered.",
"label": "Security Exchange Name",
"terseLabel": "Security Exchange Name"
}
}
},
"localname": "SecurityExchangeName",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.westpharma.com/role/CoverPage"
],
"xbrltype": "edgarExchangeCodeItemType"
},
"dei_TradingSymbol": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Trading symbol of an instrument as listed on an exchange.",
"label": "Trading Symbol",
"terseLabel": "Trading Symbol"
}
}
},
"localname": "TradingSymbol",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.westpharma.com/role/CoverPage"
],
"xbrltype": "tradingSymbolItemType"
},
"srt_AmericasMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Americas [Member]",
"terseLabel": "Americas"
}
}
},
"localname": "AmericasMember",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
],
"xbrltype": "domainItemType"
},
"srt_AsiaPacificMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Asia Pacific [Member]",
"terseLabel": "Asia Pacific"
}
}
},
"localname": "AsiaPacificMember",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
],
"xbrltype": "domainItemType"
},
"srt_ConsolidationItemsAxis": {
"auth_ref": [
"r114",
"r165",
"r177",
"r178",
"r179",
"r180",
"r181",
"r183",
"r187",
"r253",
"r254",
"r255",
"r256",
"r257",
"r258",
"r260",
"r261",
"r263",
"r265",
"r266"
],
"lang": {
"en-us": {
"role": {
"label": "Consolidation Items [Axis]",
"terseLabel": "Consolidation Items [Axis]"
}
}
},
"localname": "ConsolidationItemsAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.westpharma.com/role/SegmentInformationDetails"
],
"xbrltype": "stringItemType"
},
"srt_ConsolidationItemsDomain": {
"auth_ref": [
"r114",
"r165",
"r177",
"r178",
"r179",
"r180",
"r181",
"r183",
"r187",
"r253",
"r254",
"r255",
"r256",
"r257",
"r258",
"r260",
"r261",
"r263",
"r265",
"r266"
],
"lang": {
"en-us": {
"role": {
"label": "Consolidation Items [Domain]",
"terseLabel": "Consolidation Items [Domain]"
}
}
},
"localname": "ConsolidationItemsDomain",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.westpharma.com/role/SegmentInformationDetails"
],
"xbrltype": "domainItemType"
},
"srt_CurrencyAxis": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Currency [Axis]",
"terseLabel": "Currency [Axis]"
}
}
},
"localname": "CurrencyAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"
],
"xbrltype": "stringItemType"
},
"srt_MajorCustomersAxis": {
"auth_ref": [
"r194",
"r346",
"r352",
"r686"
],
"lang": {
"en-us": {
"role": {
"label": "Customer [Axis]",
"terseLabel": "Customer [Axis]"
}
}
},
"localname": "MajorCustomersAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
],
"xbrltype": "stringItemType"
},
"srt_MaximumMember": {
"auth_ref": [
"r247",
"r248",
"r249",
"r250",
"r271",
"r308",
"r445",
"r450",
"r633",
"r634",
"r635",
"r636",
"r637",
"r638",
"r639",
"r683",
"r687",
"r710",
"r711"
],
"lang": {
"en-us": {
"role": {
"label": "Maximum [Member]",
"terseLabel": "Maximum"
}
}
},
"localname": "MaximumMember",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails",
"http://www.westpharma.com/role/OtherIncomeExpenseNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"srt_MinimumMember": {
"auth_ref": [
"r247",
"r248",
"r249",
"r250",
"r271",
"r308",
"r445",
"r450",
"r633",
"r634",
"r635",
"r636",
"r637",
"r638",
"r639",
"r683",
"r687",
"r710",
"r711"
],
"lang": {
"en-us": {
"role": {
"label": "Minimum [Member]",
"terseLabel": "Minimum"
}
}
},
"localname": "MinimumMember",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails",
"http://www.westpharma.com/role/OtherIncomeExpenseNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"srt_NameOfMajorCustomerDomain": {
"auth_ref": [
"r194",
"r346",
"r352",
"r686"
],
"lang": {
"en-us": {
"role": {
"label": "Customer [Domain]",
"terseLabel": "Customer [Domain]"
}
}
},
"localname": "NameOfMajorCustomerDomain",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
],
"xbrltype": "domainItemType"
},
"srt_ProductOrServiceAxis": {
"auth_ref": [
"r190",
"r248",
"r249",
"r346",
"r350",
"r641",
"r682",
"r684"
],
"lang": {
"en-us": {
"role": {
"label": "Product and Service [Axis]",
"terseLabel": "Product and Service [Axis]"
}
}
},
"localname": "ProductOrServiceAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.westpharma.com/role/RevenueNarrativeDetails",
"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
],
"xbrltype": "stringItemType"
},
"srt_ProductsAndServicesDomain": {
"auth_ref": [
"r190",
"r248",
"r249",
"r346",
"r350",
"r641",
"r682",
"r684"
],
"lang": {
"en-us": {
"role": {
"label": "Product and Service [Domain]",
"terseLabel": "Product and Service [Domain]"
}
}
},
"localname": "ProductsAndServicesDomain",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.westpharma.com/role/RevenueNarrativeDetails",
"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
],
"xbrltype": "domainItemType"
},
"srt_RangeAxis": {
"auth_ref": [
"r232",
"r247",
"r248",
"r249",
"r250",
"r271",
"r308",
"r386",
"r445",
"r450",
"r478",
"r479",
"r480",
"r633",
"r634",
"r635",
"r636",
"r637",
"r638",
"r639",
"r683",
"r687",
"r710",
"r711"
],
"lang": {
"en-us": {
"role": {
"label": "Statistical Measurement [Axis]",
"terseLabel": "Statistical Measurement [Axis]"
}
}
},
"localname": "RangeAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails",
"http://www.westpharma.com/role/OtherIncomeExpenseNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"srt_RangeMember": {
"auth_ref": [
"r232",
"r247",
"r248",
"r249",
"r250",
"r271",
"r308",
"r386",
"r445",
"r450",
"r478",
"r479",
"r480",
"r633",
"r634",
"r635",
"r636",
"r637",
"r638",
"r639",
"r683",
"r687",
"r710",
"r711"
],
"lang": {
"en-us": {
"role": {
"label": "Statistical Measurement [Domain]",
"terseLabel": "Statistical Measurement [Domain]"
}
}
},
"localname": "RangeMember",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails",
"http://www.westpharma.com/role/OtherIncomeExpenseNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"srt_SegmentGeographicalDomain": {
"auth_ref": [
"r191",
"r192",
"r346",
"r351",
"r685",
"r701",
"r702",
"r703",
"r704",
"r705",
"r706",
"r707",
"r708",
"r709"
],
"lang": {
"en-us": {
"role": {
"label": "Geographical [Domain]",
"terseLabel": "Geographical [Domain]"
}
}
},
"localname": "SegmentGeographicalDomain",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
],
"xbrltype": "domainItemType"
},
"srt_StatementGeographicalAxis": {
"auth_ref": [
"r191",
"r192",
"r346",
"r351",
"r685",
"r698",
"r701",
"r702",
"r703",
"r704",
"r705",
"r706",
"r707",
"r708",
"r709"
],
"lang": {
"en-us": {
"role": {
"label": "Geographical [Axis]",
"terseLabel": "Geographical [Axis]"
}
}
},
"localname": "StatementGeographicalAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_AccountingPoliciesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Accounting Policies [Abstract]",
"terseLabel": "Accounting Policies [Abstract]"
}
}
},
"localname": "AccountingPoliciesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_AccountsPayableCurrent": {
"auth_ref": [
"r38",
"r628"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 4.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Accounts Payable, Current",
"terseLabel": "Accounts payable"
}
}
},
"localname": "AccountsPayableCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccountsReceivableNetCurrent": {
"auth_ref": [
"r196",
"r197"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 2.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
"label": "Accounts Receivable, after Allowance for Credit Loss, Current",
"terseLabel": "Accounts receivable, net"
}
}
},
"localname": "AccountsReceivableNetCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccruedIncomeTaxesCurrent": {
"auth_ref": [
"r16",
"r648",
"r665"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 6.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
"label": "Accrued Income Taxes, Current",
"terseLabel": "Income taxes payable"
}
}
},
"localname": "AccruedIncomeTaxesCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
"auth_ref": [
"r57",
"r63",
"r71",
"r72",
"r73",
"r522"
],
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
"label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
"terseLabel": "Defined benefit pension and other postretirement plans",
"verboseLabel": "Amortization of defined benefit pension and other postretirement plans:"
}
}
},
"localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails",
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
"auth_ref": [
"r12",
"r228"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 2.0,
"parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
"label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
"terseLabel": "Less: accumulated depreciation and amortization"
}
}
},
"localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
"auth_ref": [
"r63",
"r71",
"r72",
"r73",
"r74",
"r521"
],
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
"label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
"terseLabel": "(Losses) gains on derivatives",
"verboseLabel": "Gains (losses) on derivatives:"
}
}
},
"localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails",
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
"auth_ref": [
"r54",
"r55",
"r56",
"r63",
"r71",
"r72",
"r73"
],
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
"label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]",
"terseLabel": "Change in equity affiliate investment AOCI"
}
}
},
"localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
"terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
}
}
},
"localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
"auth_ref": [
"r25",
"r60",
"r62",
"r63",
"r667",
"r692",
"r695"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 5.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
"label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
"terseLabel": "Accumulated other comprehensive loss"
}
}
},
"localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
"auth_ref": [
"r71",
"r72",
"r590",
"r591",
"r592",
"r593",
"r594",
"r596"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
"label": "Accumulated Other Comprehensive Income (Loss) [Table]",
"terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
}
}
},
"localname": "AccumulatedOtherComprehensiveIncomeLossTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
"auth_ref": [
"r59",
"r63",
"r71",
"r72",
"r73",
"r116",
"r117",
"r118",
"r522",
"r621",
"r688",
"r689"
],
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
"label": "AOCI Attributable to Parent [Member]",
"terseLabel": "Accumulated other comprehensive loss"
}
}
},
"localname": "AccumulatedOtherComprehensiveIncomeMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails",
"http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_AccumulatedTranslationAdjustmentMember": {
"auth_ref": [
"r51",
"r63",
"r71",
"r72",
"r73",
"r522",
"r591",
"r592",
"r593",
"r594",
"r596"
],
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
"label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
"terseLabel": "Foreign currency translation"
}
}
},
"localname": "AccumulatedTranslationAdjustmentMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_AdditionalPaidInCapital": {
"auth_ref": [
"r23",
"r628"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 3.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
"label": "Additional Paid in Capital",
"terseLabel": "Capital in excess of par value"
}
}
},
"localname": "AdditionalPaidInCapital",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdditionalPaidInCapitalMember": {
"auth_ref": [
"r116",
"r117",
"r118",
"r488",
"r489",
"r490",
"r567"
],
"lang": {
"en-us": {
"role": {
"documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
"label": "Additional Paid-in Capital [Member]",
"terseLabel": "Capital in Excess of Par Value"
}
}
},
"localname": "AdditionalPaidInCapitalMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_AdjustmentForAmortization": {
"auth_ref": [
"r102",
"r225"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
"order": 8.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
"label": "Amortization",
"terseLabel": "Amortization"
}
}
},
"localname": "AdjustmentForAmortization",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
"terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
}
}
},
"localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
],
"xbrltype": "stringItemType"
},
"us-gaap_AllocatedShareBasedCompensationExpense": {
"auth_ref": [
"r482"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
"label": "Share-Based Payment Arrangement, Expense",
"terseLabel": "Stock-based compensation expense"
}
}
},
"localname": "AllocatedShareBasedCompensationExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/StockBasedCompensationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AmortizationOfIntangibleAssets": {
"auth_ref": [
"r102",
"r223",
"r225"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
"label": "Amortization of Intangible Assets",
"negatedLabel": "Amortization of acquisition-related intangible assets"
}
}
},
"localname": "AmortizationOfIntangibleAssets",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/SegmentInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
"auth_ref": [
"r146"
],
"lang": {
"en-us": {
"role": {
"documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
"label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
"terseLabel": "Antidilutive options excluded from computation of diluted net income per share (in shares)"
}
}
},
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/NetIncomePerShareNarrativeDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_Assets": {
"auth_ref": [
"r15",
"r111",
"r173",
"r179",
"r185",
"r204",
"r253",
"r254",
"r255",
"r257",
"r258",
"r259",
"r260",
"r262",
"r264",
"r266",
"r267",
"r519",
"r523",
"r581",
"r626",
"r628",
"r647",
"r664"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "Assets",
"totalLabel": "Total Assets"
}
}
},
"localname": "Assets",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Assets [Abstract]",
"terseLabel": "ASSETS"
}
}
},
"localname": "AssetsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "stringItemType"
},
"us-gaap_AssetsCurrent": {
"auth_ref": [
"r6",
"r37",
"r111",
"r204",
"r253",
"r254",
"r255",
"r257",
"r258",
"r259",
"r260",
"r262",
"r264",
"r266",
"r267",
"r519",
"r523",
"r581",
"r626",
"r628"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 1.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "Assets, Current",
"totalLabel": "Total current assets"
}
}
},
"localname": "AssetsCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsCurrentAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Assets, Current [Abstract]",
"terseLabel": "Current assets:"
}
}
},
"localname": "AssetsCurrentAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "stringItemType"
},
"us-gaap_AssetsFairValueDisclosure": {
"auth_ref": [
"r574"
],
"calculation": {
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "Assets, Fair Value Disclosure",
"totalLabel": "Total assets at fair value"
}
}
},
"localname": "AssetsFairValueDisclosure",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsFairValueDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Assets, Fair Value Disclosure [Abstract]",
"terseLabel": "Assets:"
}
}
},
"localname": "AssetsFairValueDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_AwardTypeAxis": {
"auth_ref": [
"r456",
"r457",
"r458",
"r459",
"r460",
"r461",
"r462",
"r463",
"r464",
"r465",
"r466",
"r467",
"r468",
"r469",
"r470",
"r471",
"r472",
"r473",
"r474",
"r475",
"r476",
"r477",
"r478",
"r479",
"r480",
"r481"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of award under share-based payment arrangement.",
"label": "Award Type [Axis]",
"terseLabel": "Award Type [Axis]"
}
}
},
"localname": "AwardTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/StockBasedCompensationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_BaseRateMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Minimum rate investor will accept.",
"label": "Base Rate [Member]",
"terseLabel": "Base Rate"
}
}
},
"localname": "BaseRateMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
"label": "Basis of Accounting, Policy [Policy Text Block]",
"terseLabel": "Basis of Presentation"
}
}
},
"localname": "BasisOfAccountingPolicyPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
"auth_ref": [
"r101",
"r516"
],
"calculation": {
"http://www.westpharma.com/role/OtherIncomeExpenseSummaryDetails": {
"order": 3.0,
"parentTag": "wst_OtherIncomeExpense",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
"label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
"terseLabel": "Contingent consideration"
}
}
},
"localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/OtherIncomeExpenseSummaryDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_BusinessCombinationContingentConsiderationLiability": {
"auth_ref": [
"r513",
"r514",
"r515"
],
"calculation": {
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": {
"order": 2.0,
"parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
"label": "Business Combination, Contingent Consideration, Liability",
"terseLabel": "Contingent consideration"
}
}
},
"localname": "BusinessCombinationContingentConsiderationLiability",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashAndCashEquivalentsAtCarryingValue": {
"auth_ref": [
"r4",
"r9",
"r104"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 1.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
"label": "Cash and Cash Equivalents, at Carrying Value",
"terseLabel": "Cash and cash equivalents"
}
}
},
"localname": "CashAndCashEquivalentsAtCarryingValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
"auth_ref": [
"r99",
"r104",
"r105"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
"periodEndLabel": "Cash, including cash equivalents at end of period",
"periodStartLabel": "Cash, including cash equivalents at beginning of period"
}
}
},
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
"auth_ref": [
"r99",
"r589"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
"totalLabel": "Net (decrease) increase in cash and cash equivalents"
}
}
},
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashFlowHedgingMember": {
"auth_ref": [
"r531"
],
"lang": {
"en-us": {
"role": {
"documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
"label": "Cash Flow Hedging [Member]",
"terseLabel": "Cash Flow Hedges:"
}
}
},
"localname": "CashFlowHedgingMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": {
"auth_ref": [
"r561"
],
"calculation": {
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails": {
"order": 2.0,
"parentTag": "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.",
"label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",
"negatedTerseLabel": "Derivative (gain) loss on derivative designed as hedging instrument, fair value hedges"
}
}
},
"localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": {
"auth_ref": [
"r561"
],
"calculation": {
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails": {
"order": 1.0,
"parentTag": "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.",
"label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge",
"negatedTerseLabel": "Derivative (gain) loss on hedged item, fair value hedges"
}
}
},
"localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ClassOfStockLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Class of Stock [Line Items]",
"terseLabel": "Class of Stock [Line Items]"
}
}
},
"localname": "ClassOfStockLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_CommitmentsAndContingencies": {
"auth_ref": [
"r47",
"r652",
"r671"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 2.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
"label": "Commitments and Contingencies",
"terseLabel": "Commitments and contingencies"
}
}
},
"localname": "CommitmentsAndContingencies",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Commitments and Contingencies Disclosure [Abstract]",
"terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
}
}
},
"localname": "CommitmentsAndContingenciesDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
"auth_ref": [
"r244",
"r245",
"r246",
"r251",
"r700"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for commitments and contingencies.",
"label": "Commitments and Contingencies Disclosure [Text Block]",
"verboseLabel": "Commitments and Contingencies"
}
}
},
"localname": "CommitmentsAndContingenciesDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CommitmentsandContingencies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_CommodityOptionMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Option contract in which the underlying asset is a commodity.",
"label": "Commodity Option [Member]",
"terseLabel": "Commodity call options"
}
}
},
"localname": "CommodityOptionMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails",
"http://www.westpharma.com/role/OtherIncomeExpenseOtherItemsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_CommonStockDividendsPerShareDeclared": {
"auth_ref": [
"r329"
],
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
"label": "Common Stock, Dividends, Per Share, Declared",
"terseLabel": "Dividends declared per share (in dollars per share)"
}
}
},
"localname": "CommonStockDividendsPerShareDeclared",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/ShareholdersEquitySupplementalEquityInformationDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_CommonStockMember": {
"auth_ref": [
"r116",
"r117",
"r567"
],
"lang": {
"en-us": {
"role": {
"documentation": "Stock that is subordinate to all other stock of the issuer.",
"label": "Common Stock [Member]",
"terseLabel": "Common Stock"
}
}
},
"localname": "CommonStockMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_CommonStockParOrStatedValuePerShare": {
"auth_ref": [
"r22"
],
"lang": {
"en-us": {
"role": {
"documentation": "Face amount or stated value per share of common stock.",
"label": "Common Stock, Par or Stated Value Per Share",
"terseLabel": "Common stock, par value (in dollars per share)"
}
}
},
"localname": "CommonStockParOrStatedValuePerShare",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"
],
"xbrltype": "perShareItemType"
},
"us-gaap_CommonStockSharesAuthorized": {
"auth_ref": [
"r22"
],
"lang": {
"en-us": {
"role": {
"documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
"label": "Common Stock, Shares Authorized",
"terseLabel": "Common stock, shares authorized (in shares)"
}
}
},
"localname": "CommonStockSharesAuthorized",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockSharesIssued": {
"auth_ref": [
"r22"
],
"lang": {
"en-us": {
"role": {
"documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
"label": "Common Stock, Shares, Issued",
"periodEndLabel": "Ending balance (in shares)",
"periodStartLabel": "Beginning balance (in shares)",
"terseLabel": "Common stock, shares issued (in shares)"
}
}
},
"localname": "CommonStockSharesIssued",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical",
"http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockSharesOutstanding": {
"auth_ref": [
"r22",
"r322"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
"label": "Common Stock, Shares, Outstanding",
"terseLabel": "Common stock, shares outstanding (in shares)"
}
}
},
"localname": "CommonStockSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockValue": {
"auth_ref": [
"r22",
"r628"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 2.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
"label": "Common Stock, Value, Issued",
"terseLabel": "Common stock, par value $0.25 per share; 200.0 million shares authorized; shares issued: 75.3\u00a0million and 75.3 million; shares outstanding: 74.0\u00a0million and 74.2 million"
}
}
},
"localname": "CommonStockValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ComprehensiveIncomeNetOfTax": {
"auth_ref": [
"r67",
"r69",
"r70",
"r80",
"r656",
"r677"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
"label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
"totalLabel": "Comprehensive income"
}
}
},
"localname": "ComprehensiveIncomeNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ComprehensiveIncomeNoteTextBlock": {
"auth_ref": [
"r79",
"r89",
"r655",
"r676"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
"label": "Comprehensive Income (Loss) Note [Text Block]",
"terseLabel": "Accumulated Other Comprehensive Loss"
}
}
},
"localname": "ComprehensiveIncomeNoteTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLoss"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ConcentrationRiskBenchmarkDomain": {
"auth_ref": [
"r158",
"r159",
"r194",
"r579",
"r580",
"r699"
],
"lang": {
"en-us": {
"role": {
"documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
"label": "Concentration Risk Benchmark [Domain]",
"terseLabel": "Concentration Risk Benchmark [Domain]"
}
}
},
"localname": "ConcentrationRiskBenchmarkDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ConcentrationRiskByBenchmarkAxis": {
"auth_ref": [
"r158",
"r159",
"r194",
"r579",
"r580",
"r696",
"r699"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by benchmark of concentration risk.",
"label": "Concentration Risk Benchmark [Axis]",
"terseLabel": "Concentration Risk Benchmark [Axis]"
}
}
},
"localname": "ConcentrationRiskByBenchmarkAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ConcentrationRiskByTypeAxis": {
"auth_ref": [
"r158",
"r159",
"r194",
"r579",
"r580",
"r696",
"r699"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
"label": "Concentration Risk Type [Axis]",
"terseLabel": "Concentration Risk Type [Axis]"
}
}
},
"localname": "ConcentrationRiskByTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ConcentrationRiskPercentage1": {
"auth_ref": [
"r158",
"r159",
"r194",
"r579",
"r580"
],
"lang": {
"en-us": {
"role": {
"documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
"label": "Concentration Risk, Percentage",
"terseLabel": "Percentage of net sales"
}
}
},
"localname": "ConcentrationRiskPercentage1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_ConcentrationRiskTypeDomain": {
"auth_ref": [
"r158",
"r159",
"r194",
"r579",
"r580",
"r699"
],
"lang": {
"en-us": {
"role": {
"documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
"label": "Concentration Risk Type [Domain]",
"terseLabel": "Concentration Risk Type [Domain]"
}
}
},
"localname": "ConcentrationRiskTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
"auth_ref": [
"r337"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
"label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
"terseLabel": "Schedule of Change in Contract with Customer, Asset and Liability"
}
}
},
"localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/RevenueTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ContractWithCustomerAssetNet": {
"auth_ref": [
"r333",
"r335",
"r347"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
"label": "Contract with Customer, Asset, after Allowance for Credit Loss",
"periodEndLabel": "Contract assets, June\u00a030, 2022",
"periodStartLabel": "Contract assets, December 31, 2021"
}
}
},
"localname": "ContractWithCustomerAssetNet",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ContractWithCustomerLiability": {
"auth_ref": [
"r333",
"r334",
"r347"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
"label": "Contract with Customer, Liability",
"negatedPeriodEndLabel": "Deferred income, June\u00a030, 2022",
"negatedPeriodStartLabel": "Deferred income, December 31, 2021",
"terseLabel": "Deferred income"
}
}
},
"localname": "ContractWithCustomerLiability",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails",
"http://www.westpharma.com/role/RevenueNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized": {
"auth_ref": [
"r336"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.",
"label": "Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized",
"terseLabel": "Change in deferred income - (increase) decrease"
}
}
},
"localname": "ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ContractWithCustomerLiabilityCurrent": {
"auth_ref": [
"r333",
"r334",
"r347"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
"label": "Contract with Customer, Liability, Current",
"terseLabel": "Deferred income, current"
}
}
},
"localname": "ContractWithCustomerLiabilityCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/RevenueNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ContractWithCustomerLiabilityNoncurrent": {
"auth_ref": [
"r333",
"r334",
"r347"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
"label": "Contract with Customer, Liability, Noncurrent",
"terseLabel": "Deferred income, noncurrent"
}
}
},
"localname": "ContractWithCustomerLiabilityNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/RevenueNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
"auth_ref": [
"r348"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
"label": "Contract with Customer, Liability, Revenue Recognized",
"terseLabel": "Revenue recognized that was included in the deferred income balance"
}
}
},
"localname": "ContractWithCustomerLiabilityRevenueRecognized",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/RevenueNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CorporateNonSegmentMember": {
"auth_ref": [
"r177",
"r178",
"r179",
"r180",
"r181",
"r187",
"r189"
],
"lang": {
"en-us": {
"role": {
"documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
"label": "Corporate, Non-Segment [Member]",
"terseLabel": "Corporate and Unallocated"
}
}
},
"localname": "CorporateNonSegmentMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/SegmentInformationDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_CostOfGoodsAndServicesSold": {
"auth_ref": [
"r83",
"r641"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
"order": 2.0,
"parentTag": "us-gaap_GrossProfit",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
"label": "Cost of Goods and Services Sold",
"negatedTerseLabel": "Cost of goods and services sold",
"verboseLabel": "Cost of goods and services sold"
}
}
},
"localname": "CostOfGoodsAndServicesSold",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails",
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CostOfSalesMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Primary financial statement caption encompassing cost of sales.",
"label": "Cost of Sales [Member]",
"terseLabel": "Cost of goods and services sold"
}
}
},
"localname": "CostOfSalesMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_CreditFacilityAxis": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
"label": "Credit Facility [Axis]",
"terseLabel": "Credit Facility [Axis]"
}
}
},
"localname": "CreditFacilityAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_CreditFacilityDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
"label": "Credit Facility [Domain]",
"terseLabel": "Credit Facility [Domain]"
}
}
},
"localname": "CreditFacilityDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_CrossCurrencyInterestRateContractMember": {
"auth_ref": [
"r387",
"r551"
],
"lang": {
"en-us": {
"role": {
"documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates.",
"label": "Cross Currency Interest Rate Contract [Member]",
"terseLabel": "Cross Currency Interest Rate Contract"
}
}
},
"localname": "CrossCurrencyInterestRateContractMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_CurrencySwapMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Swap involving the exchange of principal and interest in one currency for another currency.",
"label": "Currency Swap [Member]",
"terseLabel": "Cross-currency swap"
}
}
},
"localname": "CurrencySwapMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails",
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_CustomerConcentrationRiskMember": {
"auth_ref": [
"r155",
"r194"
],
"lang": {
"en-us": {
"role": {
"documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
"label": "Customer Concentration Risk [Member]",
"terseLabel": "Customer Concentration Risk"
}
}
},
"localname": "CustomerConcentrationRiskMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_DebtCurrent": {
"auth_ref": [
"r17"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of debt and lease obligation, classified as current.",
"label": "Debt, Current",
"terseLabel": "Long-term debt, current"
}
}
},
"localname": "DebtCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Debt Disclosure [Abstract]",
"terseLabel": "Debt Disclosure [Abstract]"
}
}
},
"localname": "DebtDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_DebtDisclosureTextBlock": {
"auth_ref": [
"r107",
"r274",
"r275",
"r276",
"r277",
"r278",
"r279",
"r280",
"r285",
"r292",
"r293",
"r295",
"r302"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
"label": "Debt Disclosure [Text Block]",
"verboseLabel": "Debt"
}
}
},
"localname": "DebtDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/Debt"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
"label": "Debt Instrument, Basis Spread on Variable Rate",
"terseLabel": "Debt instrument, basis spread on interest rate"
}
}
},
"localname": "DebtInstrumentBasisSpreadOnVariableRate1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_DebtInstrumentCarryingAmount": {
"auth_ref": [
"r18",
"r296",
"r649",
"r662"
],
"calculation": {
"http://www.westpharma.com/role/DebtLongtermDebtDetails_1": {
"order": 2.0,
"parentTag": "us-gaap_LongTermDebt",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
"label": "Long-Term Debt, Gross",
"terseLabel": "Long-term debt, gross"
}
}
},
"localname": "DebtInstrumentCarryingAmount",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DebtLongtermDebtDetails",
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtInstrumentInterestRateStatedPercentage": {
"auth_ref": [
"r44",
"r269"
],
"lang": {
"en-us": {
"role": {
"documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
"label": "Debt Instrument, Interest Rate, Stated Percentage",
"terseLabel": "Debt instrument, stated interest rate"
}
}
},
"localname": "DebtInstrumentInterestRateStatedPercentage",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DebtLongtermDebtDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_DebtInstrumentLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Debt Instrument [Line Items]",
"terseLabel": "Debt Instrument [Line Items]"
}
}
},
"localname": "DebtInstrumentLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DebtLongtermDebtDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DebtInstrumentTable": {
"auth_ref": [
"r45",
"r110",
"r114",
"r268",
"r269",
"r270",
"r271",
"r272",
"r273",
"r275",
"r281",
"r282",
"r283",
"r284",
"r286",
"r287",
"r288",
"r289",
"r290",
"r291",
"r294",
"r298",
"r299",
"r300",
"r301",
"r323",
"r326",
"r327",
"r328",
"r599",
"r600",
"r602",
"r603",
"r661"
],
"lang": {
"en-us": {
"role": {
"documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
"label": "Schedule of Long-Term Debt Instruments [Table]",
"terseLabel": "Schedule of Long-term Debt Instruments [Table]"
}
}
},
"localname": "DebtInstrumentTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DebtLongtermDebtDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": {
"auth_ref": [
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 7.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).",
"label": "Deferred Compensation Liability, Classified, Noncurrent",
"verboseLabel": "Deferred compensation benefits"
}
}
},
"localname": "DeferredCompensationLiabilityClassifiedNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DeferredCompensationPlanAssets": {
"auth_ref": [
"r14"
],
"calculation": {
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": {
"order": 3.0,
"parentTag": "us-gaap_AssetsFairValueDisclosure",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying amount as of the balance sheet date of assets held under deferred compensation agreements.",
"label": "Deferred Compensation Plan Assets",
"terseLabel": "Deferred compensation assets"
}
}
},
"localname": "DeferredCompensationPlanAssets",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DeferredIncomeTaxAssetsNet": {
"auth_ref": [
"r494",
"r495"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 7.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
"label": "Deferred Income Tax Assets, Net",
"terseLabel": "Deferred income taxes"
}
}
},
"localname": "DeferredIncomeTaxAssetsNet",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DeferredIncomeTaxLiabilitiesNet": {
"auth_ref": [
"r494",
"r495"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 3.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
"label": "Deferred Income Tax Liabilities, Net",
"terseLabel": "Deferred income taxes"
}
}
},
"localname": "DeferredIncomeTaxLiabilitiesNet",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DefinedBenefitPlanActuarialGainLoss": {
"auth_ref": [
"r370"
],
"calculation": {
"http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": {
"order": 5.0,
"parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.",
"label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)",
"negatedTerseLabel": "Recognized actuarial losses (gains)",
"terseLabel": "Actuarial losses"
}
}
},
"localname": "DefinedBenefitPlanActuarialGainLoss",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails",
"http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
"auth_ref": [
"r363",
"r403",
"r430",
"r435",
"r436"
],
"calculation": {
"http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": {
"order": 4.0,
"parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
"label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
"negatedTerseLabel": "Prior service credit",
"terseLabel": "Amortization of prior service credit"
}
}
},
"localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails",
"http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
"auth_ref": [
"r361",
"r362",
"r385",
"r435",
"r646",
"r663"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 8.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.",
"label": "Assets for Plan Benefits, Defined Benefit Plan",
"terseLabel": "Pension and other postretirement benefits"
}
}
},
"localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
"auth_ref": [
"r363",
"r401",
"r428",
"r435",
"r436"
],
"calculation": {
"http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": {
"order": 3.0,
"parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
"label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
"negatedLabel": "Expected return on assets"
}
}
},
"localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DefinedBenefitPlanInterestCost": {
"auth_ref": [
"r363",
"r368",
"r400",
"r427",
"r435",
"r436"
],
"calculation": {
"http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": {
"order": 2.0,
"parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
"label": "Defined Benefit Plan, Interest Cost",
"terseLabel": "Interest cost"
}
}
},
"localname": "DefinedBenefitPlanInterestCost",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
"auth_ref": [
"r398",
"r425",
"r435",
"r436"
],
"calculation": {
"http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
"label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
"totalLabel": "Net periodic benefit cost"
}
}
},
"localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DefinedBenefitPlanOtherCosts": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of defined benefit plan cost (credit), classified as other.",
"label": "Defined Benefit Plan, Other Cost (Credit)",
"negatedTerseLabel": "Other"
}
}
},
"localname": "DefinedBenefitPlanOtherCosts",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments": {
"auth_ref": [
"r364",
"r405",
"r432"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
"order": 7.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees.",
"label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment",
"negatedTerseLabel": "Pension settlement charge"
}
}
},
"localname": "DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": {
"auth_ref": [
"r364",
"r405",
"r432"
],
"calculation": {
"http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": {
"order": 6.0,
"parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.",
"label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement",
"negatedLabel": "Settlements",
"negatedTerseLabel": "Settlements",
"terseLabel": "Settlements"
}
}
},
"localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails",
"http://www.westpharma.com/role/BenefitPlansNarrativeDetails",
"http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DefinedBenefitPlanServiceCost": {
"auth_ref": [
"r366",
"r399",
"r426",
"r435",
"r436"
],
"calculation": {
"http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": {
"order": 1.0,
"parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
"label": "Defined Benefit Plan, Service Cost",
"terseLabel": "Service cost"
}
}
},
"localname": "DefinedBenefitPlanServiceCost",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]",
"terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]"
}
}
},
"localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": {
"auth_ref": [
"r419",
"r420",
"r423",
"r424",
"r435"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosures and provisions pertaining to defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans.",
"label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]",
"terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]"
}
}
},
"localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/BenefitPlansNarrativeDetails",
"http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]",
"terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]"
}
}
},
"localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/BenefitPlansNarrativeDetails",
"http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_Depreciation": {
"auth_ref": [
"r102",
"r226"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
"label": "Depreciation",
"terseLabel": "Depreciation"
}
}
},
"localname": "Depreciation",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DerivativeAveragePriceRiskOptionStrikePrice": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The average strike price on the group of price risk option contracts such as put options or call options.",
"label": "Derivative, Average Price Risk Option Strike Price",
"terseLabel": "Derivative, average price risk option strike price"
}
}
},
"localname": "DerivativeAveragePriceRiskOptionStrikePrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"
],
"xbrltype": "perUnitItemType"
},
"us-gaap_DerivativeContractTypeDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
"label": "Derivative Contract [Domain]",
"terseLabel": "Derivative Contract Type [Domain]"
}
}
},
"localname": "DerivativeContractTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails",
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails",
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails",
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails",
"http://www.westpharma.com/role/OtherIncomeExpenseOtherItemsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings": {
"auth_ref": [
"r542",
"r559"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method.",
"label": "Derivative, Excluded Component, Gain (Loss), Recognized in Earnings",
"negatedTerseLabel": "Derivative, forward point components, (gain) loss, recognized in earnings"
}
}
},
"localname": "DerivativeExcludedComponentGainLossRecognizedInEarnings",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DerivativeInstrumentRiskAxis": {
"auth_ref": [
"r50",
"r535",
"r537",
"r545",
"r553"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of derivative contract.",
"label": "Derivative Instrument [Axis]",
"terseLabel": "Derivative Instrument [Axis]"
}
}
},
"localname": "DerivativeInstrumentRiskAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails",
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails",
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails",
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails",
"http://www.westpharma.com/role/OtherIncomeExpenseOtherItemsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
"terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
}
}
},
"localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
"auth_ref": [
"r564",
"r573"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
"label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
"verboseLabel": "Derivative Financial Instruments"
}
}
},
"localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstruments"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
"auth_ref": [
"r533",
"r535",
"r545"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of hedging relationship.",
"label": "Hedging Relationship [Axis]",
"terseLabel": "Hedging Relationship [Axis]"
}
}
},
"localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails",
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
"auth_ref": [
"r533",
"r535",
"r545",
"r553",
"r554",
"r557",
"r563"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
"label": "Derivative Instruments, Gain (Loss) [Table]",
"terseLabel": "Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]"
}
}
},
"localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails",
"http://www.westpharma.com/role/OtherIncomeExpenseOtherItemsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DerivativeInstrumentsGainLossLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Derivative Instruments, Gain (Loss) [Line Items]",
"terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
}
}
},
"localname": "DerivativeInstrumentsGainLossLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails",
"http://www.westpharma.com/role/OtherIncomeExpenseOtherItemsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
"auth_ref": [
"r543",
"r546"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
"label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
"terseLabel": "Derivative instruments not designated as hedging instruments, gain (loss), net"
}
}
},
"localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails",
"http://www.westpharma.com/role/OtherIncomeExpenseOtherItemsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DerivativeLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Derivative [Line Items]",
"terseLabel": "Derivative [Line Items]"
}
}
},
"localname": "DerivativeLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DerivativeNonmonetaryNotionalAmountVolume": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Nominal volume used to calculate payments on a derivative instrument.",
"label": "Derivative, Nonmonetary Notional Amount, Volume",
"terseLabel": "Derivative, nonmonetary notional amount, volume"
}
}
},
"localname": "DerivativeNonmonetaryNotionalAmountVolume",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"
],
"xbrltype": "volumeItemType"
},
"us-gaap_DerivativeNotionalAmount": {
"auth_ref": [
"r527",
"r529"
],
"lang": {
"en-us": {
"role": {
"documentation": "Nominal or face amount used to calculate payment on derivative.",
"label": "Derivative, Notional Amount",
"terseLabel": "Derivative, notional amount"
}
}
},
"localname": "DerivativeNotionalAmount",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DerivativeTable": {
"auth_ref": [
"r526",
"r528",
"r529",
"r533",
"r534",
"r538",
"r545",
"r555",
"r556",
"r563",
"r564"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
"label": "Derivative [Table]",
"terseLabel": "Derivative [Table]"
}
}
},
"localname": "DerivativeTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DerivativeTermOfContract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
"label": "Derivative, Term of Contract",
"terseLabel": "Derivative contract term"
}
}
},
"localname": "DerivativeTermOfContract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_DesignatedAsHedgingInstrumentMember": {
"auth_ref": [
"r533"
],
"lang": {
"en-us": {
"role": {
"documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
"label": "Designated as Hedging Instrument [Member]",
"terseLabel": "Designated as Hedging Instrument"
}
}
},
"localname": "DesignatedAsHedgingInstrumentMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_DisaggregationOfRevenueLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Disaggregation of Revenue [Line Items]",
"terseLabel": "Disaggregation of Revenue [Line Items]"
}
}
},
"localname": "DisaggregationOfRevenueLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/RevenueNarrativeDetails",
"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DisaggregationOfRevenueTable": {
"auth_ref": [
"r346",
"r350",
"r351",
"r352",
"r353",
"r354",
"r355",
"r356"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
"label": "Disaggregation of Revenue [Table]",
"terseLabel": "Disaggregation of Revenue [Table]"
}
}
},
"localname": "DisaggregationOfRevenueTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/RevenueNarrativeDetails",
"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DisaggregationOfRevenueTableTextBlock": {
"auth_ref": [
"r346"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
"label": "Disaggregation of Revenue [Table Text Block]",
"terseLabel": "Schedule of Disaggregation of Revenue"
}
}
},
"localname": "DisaggregationOfRevenueTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/RevenueTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
"auth_ref": [
"r455",
"r456",
"r483",
"r484",
"r485",
"r491"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for share-based payment arrangement.",
"label": "Share-Based Payment Arrangement [Text Block]",
"verboseLabel": "Stock-Based Compensation"
}
}
},
"localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/StockBasedCompensation"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Share-Based Payment Arrangement [Abstract]",
"terseLabel": "Share-based Payment Arrangement [Abstract]"
}
}
},
"localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_DividendsCommonStockCash": {
"auth_ref": [
"r329"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
"label": "Dividends, Common Stock, Cash",
"negatedTerseLabel": "Dividends declared"
}
}
},
"localname": "DividendsCommonStockCash",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DomesticLineOfCreditMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars, inside the reporting entity's home country.",
"label": "Domestic Line of Credit [Member]",
"terseLabel": "Domestic Line of Credit"
}
}
},
"localname": "DomesticLineOfCreditMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_DomesticPlanMember": {
"auth_ref": [
"r440",
"r444",
"r449"
],
"lang": {
"en-us": {
"role": {
"documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
"label": "Domestic Plan [Member]",
"terseLabel": "Domestic Plan"
}
}
},
"localname": "DomesticPlanMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_DueFromAffiliates": {
"auth_ref": [
"r623",
"r624",
"r673"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "For an unclassified balance sheet, amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership.",
"label": "Due from Affiliates",
"terseLabel": "Amount receivable from affiliates"
}
}
},
"localname": "DueFromAffiliates",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AffiliatedCompaniesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DueToAffiliateCurrentAndNoncurrent": {
"auth_ref": [
"r623",
"r625",
"r651",
"r672",
"r697"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership.",
"label": "Due to Affiliate",
"terseLabel": "Amount due and payable to affiliates"
}
}
},
"localname": "DueToAffiliateCurrentAndNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AffiliatedCompaniesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EMEAMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Regions of Europe, Middle East and Africa.",
"label": "EMEA [Member]",
"terseLabel": "Europe, Middle East, Africa"
}
}
},
"localname": "EMEAMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_EarningsPerShareAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Earnings Per Share [Abstract]",
"terseLabel": "Earnings Per Share [Abstract]",
"verboseLabel": "Net income per share:"
}
}
},
"localname": "EarningsPerShareAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
],
"xbrltype": "stringItemType"
},
"us-gaap_EarningsPerShareBasic": {
"auth_ref": [
"r81",
"r125",
"r126",
"r127",
"r128",
"r129",
"r136",
"r138",
"r143",
"r144",
"r145",
"r149",
"r150",
"r568",
"r569",
"r657",
"r678"
],
"lang": {
"en-us": {
"role": {
"documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
"label": "Earnings Per Share, Basic",
"terseLabel": "Basic (in dollars per share)"
}
}
},
"localname": "EarningsPerShareBasic",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
],
"xbrltype": "perShareItemType"
},
"us-gaap_EarningsPerShareDiluted": {
"auth_ref": [
"r81",
"r125",
"r126",
"r127",
"r128",
"r129",
"r138",
"r143",
"r144",
"r145",
"r149",
"r150",
"r568",
"r569",
"r657",
"r678"
],
"lang": {
"en-us": {
"role": {
"documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
"label": "Earnings Per Share, Diluted",
"terseLabel": "Diluted (in dollars per share)"
}
}
},
"localname": "EarningsPerShareDiluted",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
],
"xbrltype": "perShareItemType"
},
"us-gaap_EarningsPerShareTextBlock": {
"auth_ref": [
"r146",
"r147",
"r148",
"r151"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for earnings per share.",
"label": "Earnings Per Share [Text Block]",
"verboseLabel": "Net Income Per Share"
}
}
},
"localname": "EarningsPerShareTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/NetIncomePerShare"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
"auth_ref": [
"r589"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
"order": 4.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
"terseLabel": "Effect of exchange rates on cash"
}
}
},
"localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EffectOnFutureEarningsAmount": {
"auth_ref": [
"r240"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The quantified amount of the future effect on earnings.",
"label": "Effect on Future Earnings, Amount",
"terseLabel": "Effect on future earnings, amount"
}
}
},
"localname": "EffectOnFutureEarningsAmount",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/OtherIncomeExpenseNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
"auth_ref": [
"r497"
],
"lang": {
"en-us": {
"role": {
"documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
"label": "Effective Income Tax Rate Reconciliation, Percent",
"terseLabel": "Effective income tax rate"
}
}
},
"localname": "EffectiveIncomeTaxRateContinuingOperations",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/IncomeTaxesDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_EmployeeSeveranceMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
"label": "Employee Severance [Member]",
"terseLabel": "Severance and benefits"
}
}
},
"localname": "EmployeeSeveranceMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/OtherIncomeExpenseRestructuringandRelatedChargesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_EquityAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Equity [Abstract]",
"terseLabel": "Equity:"
}
}
},
"localname": "EquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "stringItemType"
},
"us-gaap_EquityComponentDomain": {
"auth_ref": [
"r0",
"r71",
"r72",
"r73",
"r116",
"r117",
"r118",
"r122",
"r130",
"r132",
"r152",
"r206",
"r322",
"r329",
"r488",
"r489",
"r490",
"r501",
"r502",
"r567",
"r590",
"r591",
"r592",
"r593",
"r594",
"r596",
"r621",
"r688",
"r689",
"r690"
],
"lang": {
"en-us": {
"role": {
"documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
"label": "Equity Component [Domain]",
"terseLabel": "Equity Component [Domain]"
}
}
},
"localname": "EquityComponentDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails",
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails",
"http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_EquityMethodInvestments": {
"auth_ref": [
"r10",
"r174",
"r203"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
"label": "Equity Method Investments",
"terseLabel": "Carrying amount, equity-method investments"
}
}
},
"localname": "EquityMethodInvestments",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AffiliatedCompaniesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Equity Method Investments and Joint Ventures [Abstract]",
"terseLabel": "Equity Method Investments and Joint Ventures [Abstract]"
}
}
},
"localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
"auth_ref": [
"r205"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
"label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
"terseLabel": "Affiliated Companies"
}
}
},
"localname": "EquityMethodInvestmentsDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AffiliatedCompanies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
"auth_ref": [
"r202",
"r679"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
"label": "Equity Securities, FV-NI, Realized Gain (Loss)",
"terseLabel": "Net gain on sale of cost investments"
}
}
},
"localname": "EquitySecuritiesFvNiRealizedGainLoss",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/OtherIncomeExpenseOtherItemsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
"auth_ref": [
"r202",
"r679"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
"label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
"negatedTerseLabel": "Impairment charge from cost investments"
}
}
},
"localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/OtherIncomeExpenseOtherItemsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
"auth_ref": [
"r201"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of investment in equity security without readily determinable fair value.",
"label": "Equity Securities without Readily Determinable Fair Value, Amount",
"terseLabel": "Carrying amount, investments not accounted for under the equity method"
}
}
},
"localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AffiliatedCompaniesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
"terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
}
}
},
"localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
"auth_ref": [
"r574",
"r575",
"r578"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
"label": "Fair Value, Recurring and Nonrecurring [Table]",
"terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]"
}
}
},
"localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueByFairValueHierarchyLevelAxis": {
"auth_ref": [
"r283",
"r298",
"r299",
"r387",
"r389",
"r390",
"r391",
"r392",
"r393",
"r394",
"r435",
"r575",
"r630",
"r631",
"r632"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
"label": "Fair Value Hierarchy and NAV [Axis]",
"terseLabel": "Fair Value Hierarchy and NAV [Axis]"
}
}
},
"localname": "FairValueByFairValueHierarchyLevelAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueByLiabilityClassAxis": {
"auth_ref": [
"r577",
"r578"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by class of liability.",
"label": "Liability Class [Axis]",
"terseLabel": "Liability Class [Axis]"
}
}
},
"localname": "FairValueByLiabilityClassAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueDisclosuresAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Fair Value Disclosures [Abstract]",
"terseLabel": "Fair Value Disclosures [Abstract]"
}
}
},
"localname": "FairValueDisclosuresAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_FairValueDisclosuresTextBlock": {
"auth_ref": [
"r577"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
"label": "Fair Value Disclosures [Text Block]",
"verboseLabel": "Fair Value Measurements"
}
}
},
"localname": "FairValueDisclosuresTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/FairValueMeasurements"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_FairValueHedgingMember": {
"auth_ref": [
"r530"
],
"lang": {
"en-us": {
"role": {
"documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
"label": "Fair Value Hedging [Member]",
"terseLabel": "Fair Value Hedges"
}
}
},
"localname": "FairValueHedgingMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails",
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueInputsLevel1Member": {
"auth_ref": [
"r283",
"r387",
"r389",
"r394",
"r435",
"r575",
"r630"
],
"lang": {
"en-us": {
"role": {
"documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
"label": "Fair Value, Inputs, Level 1 [Member]",
"terseLabel": "Level 1"
}
}
},
"localname": "FairValueInputsLevel1Member",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueInputsLevel2Member": {
"auth_ref": [
"r283",
"r298",
"r299",
"r387",
"r389",
"r394",
"r435",
"r575",
"r631"
],
"lang": {
"en-us": {
"role": {
"documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
"label": "Fair Value, Inputs, Level 2 [Member]",
"terseLabel": "Level 2"
}
}
},
"localname": "FairValueInputsLevel2Member",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueInputsLevel3Member": {
"auth_ref": [
"r283",
"r298",
"r299",
"r387",
"r389",
"r390",
"r391",
"r392",
"r393",
"r394",
"r435",
"r575",
"r632"
],
"lang": {
"en-us": {
"role": {
"documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
"label": "Fair Value, Inputs, Level 3 [Member]",
"terseLabel": "Level 3"
}
}
},
"localname": "FairValueInputsLevel3Member",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
"auth_ref": [
"r576"
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents classes of liabilities measured and disclosed at fair value.",
"label": "Fair Value by Liability Class [Domain]",
"terseLabel": "Fair Value by Liability Class [Domain]"
}
}
},
"localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
"auth_ref": [
"r283",
"r298",
"r299",
"r387",
"r389",
"r390",
"r391",
"r392",
"r393",
"r394",
"r435",
"r630",
"r631",
"r632"
],
"lang": {
"en-us": {
"role": {
"documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
"label": "Fair Value Hierarchy and NAV [Domain]",
"terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
}
}
},
"localname": "FairValueMeasurementsFairValueHierarchyDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FederalFundsEffectiveSwapRateMember": {
"auth_ref": [
"r558"
],
"lang": {
"en-us": {
"role": {
"documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.",
"label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]",
"terseLabel": "Federal Funds Effective Rate Plus"
}
}
},
"localname": "FederalFundsEffectiveSwapRateMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": {
"auth_ref": [
],
"calculation": {
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": {
"order": 1.0,
"parentTag": "us-gaap_AssetsFairValueDisclosure",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.",
"label": "Foreign Currency Contract, Asset, Fair Value Disclosure",
"terseLabel": "Foreign currency contracts"
}
}
},
"localname": "ForeignCurrencyContractAssetFairValueDisclosure",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": {
"auth_ref": [
],
"calculation": {
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": {
"order": 1.0,
"parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.",
"label": "Foreign Currency Contracts, Liability, Fair Value Disclosure",
"terseLabel": "Foreign currency contracts"
}
}
},
"localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ForeignCurrencyGainLossMember": {
"auth_ref": [
"r552"
],
"lang": {
"en-us": {
"role": {
"documentation": "Primary financial statement caption encompassing foreign currency gain (loss).",
"label": "Foreign Currency Gain (Loss) [Member]",
"terseLabel": "Other (income) expense"
}
}
},
"localname": "ForeignCurrencyGainLossMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails",
"http://www.westpharma.com/role/OtherIncomeExpenseOtherItemsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
"auth_ref": [
"r585",
"r586",
"r587",
"r588"
],
"calculation": {
"http://www.westpharma.com/role/OtherIncomeExpenseSummaryDetails": {
"order": 4.0,
"parentTag": "wst_OtherIncomeExpense",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
"label": "Foreign Currency Transaction Gain (Loss), before Tax",
"negatedTerseLabel": "Foreign exchange transaction gains"
}
}
},
"localname": "ForeignCurrencyTransactionGainLossBeforeTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/OtherIncomeExpenseSummaryDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ForeignExchangeContractMember": {
"auth_ref": [
"r50",
"r387",
"r550"
],
"lang": {
"en-us": {
"role": {
"documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
"label": "Foreign Exchange Contract [Member]",
"terseLabel": "Foreign currency hedge contracts",
"verboseLabel": "Foreign currency contracts"
}
}
},
"localname": "ForeignExchangeContractMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails",
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails",
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ForeignExchangeForwardMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.",
"label": "Foreign Exchange Forward [Member]",
"terseLabel": "Foreign Exchange Forward"
}
}
},
"localname": "ForeignExchangeForwardMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ForeignLineOfCreditMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars, outside the reporting entity's home country.",
"label": "Foreign Line of Credit [Member]",
"terseLabel": "Foreign Line of Credit"
}
}
},
"localname": "ForeignLineOfCreditMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ForeignPlanMember": {
"auth_ref": [
"r440",
"r444",
"r449"
],
"lang": {
"en-us": {
"role": {
"documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
"label": "Foreign Plan [Member]",
"terseLabel": "International plans"
}
}
},
"localname": "ForeignPlanMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ForwardContractsMember": {
"auth_ref": [
"r549"
],
"lang": {
"en-us": {
"role": {
"documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date.",
"label": "Forward Contracts [Member]",
"terseLabel": "Forward Contracts"
}
}
},
"localname": "ForwardContractsMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet": {
"auth_ref": [
"r542",
"r562"
],
"calculation": {
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails": {
"order": 3.0,
"parentTag": "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Net gain (loss) relating to components of the gain (loss) on the fair value hedging instrument excluded from the assessment of fair value hedge effectiveness. Recognized in earnings.",
"label": "Gain (Loss) from Components Excluded from Assessment of Fair Value Hedge Effectiveness, Net",
"negatedTerseLabel": "Derivative (gain) loss on amount excluded from effectiveness testing, fair value hedges"
}
}
},
"localname": "GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
"auth_ref": [
"r535"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.",
"label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
"terseLabel": "Gain (loss) on derivative instruments, net, pretax"
}
}
},
"localname": "GainLossOnDerivativeInstrumentsNetPretax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings": {
"auth_ref": [
"r539"
],
"calculation": {
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total amount of gain (loss) derived from fair value hedges recognized in earnings in the period.",
"label": "Gain (Loss) on Fair Value Hedges Recognized in Earnings",
"negatedTotalLabel": "Derivative (gain) loss recognized in income, fair value hedges"
}
}
},
"localname": "GainLossOnFairValueHedgesRecognizedInEarnings",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": {
"auth_ref": [
"r102"
],
"calculation": {
"http://www.westpharma.com/role/OtherIncomeExpenseSummaryDetails": {
"order": 5.0,
"parentTag": "wst_OtherIncomeExpense",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.",
"label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges",
"negatedTerseLabel": "Fixed asset impairments and loss on sale of equipment"
}
}
},
"localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/OtherIncomeExpenseSummaryDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GeneralAndAdministrativeExpense": {
"auth_ref": [
"r84"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
"label": "General and Administrative Expense",
"negatedTerseLabel": "Corporate general costs"
}
}
},
"localname": "GeneralAndAdministrativeExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/SegmentInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GeographicConcentrationRiskMember": {
"auth_ref": [
"r157",
"r699"
],
"lang": {
"en-us": {
"role": {
"documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).",
"label": "Geographic Concentration Risk [Member]",
"terseLabel": "Geographic Concentration Risk"
}
}
},
"localname": "GeographicConcentrationRiskMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_Goodwill": {
"auth_ref": [
"r13",
"r211",
"r212",
"r219",
"r221",
"r628",
"r645"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 5.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
"label": "Goodwill",
"terseLabel": "Goodwill"
}
}
},
"localname": "Goodwill",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GrossProfit": {
"auth_ref": [
"r82",
"r111",
"r173",
"r178",
"r181",
"r184",
"r187",
"r204",
"r253",
"r254",
"r255",
"r258",
"r259",
"r260",
"r262",
"r264",
"r266",
"r267",
"r581"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
"order": 2.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
"label": "Gross Profit",
"totalLabel": "Gross profit"
}
}
},
"localname": "GrossProfit",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_HedgingDesignationAxis": {
"auth_ref": [
"r533",
"r554"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by designation of purpose of derivative instrument.",
"label": "Hedging Designation [Axis]",
"terseLabel": "Hedging Designation [Axis]"
}
}
},
"localname": "HedgingDesignationAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails",
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails",
"http://www.westpharma.com/role/OtherIncomeExpenseOtherItemsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_HedgingDesignationDomain": {
"auth_ref": [
"r533"
],
"lang": {
"en-us": {
"role": {
"documentation": "Designation of purpose of derivative instrument.",
"label": "Hedging Designation [Domain]",
"terseLabel": "Hedging Designation [Domain]"
}
}
},
"localname": "HedgingDesignationDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails",
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails",
"http://www.westpharma.com/role/OtherIncomeExpenseOtherItemsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_HedgingRelationshipDomain": {
"auth_ref": [
"r533"
],
"lang": {
"en-us": {
"role": {
"documentation": "Nature or intent of a hedge.",
"label": "Hedging Relationship [Domain]",
"terseLabel": "Hedging Relationship [Domain]"
}
}
},
"localname": "HedgingRelationshipDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails",
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
"auth_ref": [
"r173",
"r178",
"r181",
"r184",
"r187"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
"order": 1.0,
"parentTag": "us-gaap_NetIncomeLoss",
"weight": 1.0
},
"http://www.westpharma.com/role/SegmentInformationDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
"label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
"totalLabel": "Income before income taxes"
}
}
},
"localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails",
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
"http://www.westpharma.com/role/SegmentInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncomeLossFromEquityMethodInvestments": {
"auth_ref": [
"r77",
"r102",
"r170",
"r203",
"r653",
"r674"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
"order": 3.0,
"parentTag": "us-gaap_NetIncomeLoss",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
"label": "Income (Loss) from Equity Method Investments",
"negatedTerseLabel": "Equity in net income of affiliated companies"
}
}
},
"localname": "IncomeLossFromEquityMethodInvestments",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncomeStatementAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Income Statement [Abstract]",
"terseLabel": "Income Statement [Abstract]"
}
}
},
"localname": "IncomeStatementAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_IncomeStatementLocationAxis": {
"auth_ref": [
"r230",
"r236"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by location in the income statement.",
"label": "Income Statement Location [Axis]",
"terseLabel": "Income Statement Location [Axis]"
}
}
},
"localname": "IncomeStatementLocationAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails",
"http://www.westpharma.com/role/OtherIncomeExpenseOtherItemsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncomeStatementLocationDomain": {
"auth_ref": [
"r236"
],
"lang": {
"en-us": {
"role": {
"documentation": "Location in the income statement.",
"label": "Income Statement Location [Domain]",
"terseLabel": "Income Statement Location [Domain]"
}
}
},
"localname": "IncomeStatementLocationDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails",
"http://www.westpharma.com/role/OtherIncomeExpenseOtherItemsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_IncomeTaxDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Income Tax Disclosure [Abstract]",
"terseLabel": "Income Tax Disclosure [Abstract]"
}
}
},
"localname": "IncomeTaxDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_IncomeTaxDisclosureTextBlock": {
"auth_ref": [
"r112",
"r498",
"r499",
"r500",
"r506",
"r508",
"r510",
"r511",
"r512"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
"label": "Income Tax Disclosure [Text Block]",
"verboseLabel": "Income Taxes"
}
}
},
"localname": "IncomeTaxDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/IncomeTaxes"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_IncomeTaxExpenseBenefit": {
"auth_ref": [
"r113",
"r131",
"r132",
"r171",
"r496",
"r507",
"r509",
"r680"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
"order": 2.0,
"parentTag": "us-gaap_NetIncomeLoss",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
"label": "Income Tax Expense (Benefit)",
"negatedTerseLabel": "Tax benefit",
"terseLabel": "Provision for income taxes",
"verboseLabel": "Income tax expense"
}
}
},
"localname": "IncomeTaxExpenseBenefit",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails",
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
"http://www.westpharma.com/role/IncomeTaxesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
"auth_ref": [
"r101"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
"order": 6.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
"label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
"negatedTerseLabel": "Changes in assets and liabilities"
}
}
},
"localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
"label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
"terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
"verboseLabel": "Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]"
}
}
},
"localname": "IncreaseDecreaseInStockholdersEquityRollForward",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails",
"http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
"auth_ref": [
"r139",
"r140",
"r141",
"r145",
"r454"
],
"calculation": {
"http://www.westpharma.com/role/NetIncomePerShareSummaryofNetIncomePerShareDetails": {
"order": 2.0,
"parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
"weight": 1.0
}
},
"lang": {
"en-us": {
"role": {
"documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
"label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
"terseLabel": "Dilutive effect of equity awards, based on the treasury stock method (in shares)"
}
}
},
"localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/NetIncomePerShareSummaryofNetIncomePerShareDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_IntangibleAssetsNetExcludingGoodwill": {
"auth_ref": [
"r222",
"r224"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 6.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
"label": "Intangible Assets, Net (Excluding Goodwill)",
"terseLabel": "Intangible assets, net"
}
}
},
"localname": "IntangibleAssetsNetExcludingGoodwill",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InterestExpense": {
"auth_ref": [
"r75",
"r167",
"r598",
"r601",
"r658"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
"order": 2.0,
"parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
"label": "Interest Expense",
"negatedTerseLabel": "Interest expense",
"terseLabel": "Interest expense, net"
}
}
},
"localname": "InterestExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails",
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InterestExpenseMember": {
"auth_ref": [
"r552"
],
"lang": {
"en-us": {
"role": {
"documentation": "Primary financial statement caption encompassing interest expense.",
"label": "Interest Expense [Member]",
"terseLabel": "Interest expense"
}
}
},
"localname": "InterestExpenseMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_IntersegmentEliminationMember": {
"auth_ref": [
"r165",
"r177",
"r178",
"r179",
"r180",
"r181",
"r183",
"r187"
],
"lang": {
"en-us": {
"role": {
"documentation": "Eliminating entries used in operating segment consolidation.",
"label": "Intersegment Eliminations [Member]",
"terseLabel": "Intersegment sales elimination"
}
}
},
"localname": "IntersegmentEliminationMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/SegmentInformationDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_InventoryDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Inventory Disclosure [Abstract]",
"terseLabel": "Inventory Disclosure [Abstract]"
}
}
},
"localname": "InventoryDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_InventoryDisclosureTextBlock": {
"auth_ref": [
"r210"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
"label": "Inventory Disclosure [Text Block]",
"verboseLabel": "Inventories"
}
}
},
"localname": "InventoryDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/Inventories"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_InventoryFinishedGoodsNetOfReserves": {
"auth_ref": [
"r29",
"r209"
],
"calculation": {
"http://www.westpharma.com/role/InventoriesDetails": {
"order": 1.0,
"parentTag": "us-gaap_InventoryNet",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
"label": "Inventory, Finished Goods, Net of Reserves",
"terseLabel": "Finished goods"
}
}
},
"localname": "InventoryFinishedGoodsNetOfReserves",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/InventoriesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InventoryNet": {
"auth_ref": [
"r5",
"r35",
"r628"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 3.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
},
"http://www.westpharma.com/role/InventoriesDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
"label": "Inventory, Net",
"totalLabel": "Total inventories",
"verboseLabel": "Inventories"
}
}
},
"localname": "InventoryNet",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED",
"http://www.westpharma.com/role/InventoriesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InventoryRawMaterialsNetOfReserves": {
"auth_ref": [
"r31",
"r209"
],
"calculation": {
"http://www.westpharma.com/role/InventoriesDetails": {
"order": 3.0,
"parentTag": "us-gaap_InventoryNet",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
"label": "Inventory, Raw Materials, Net of Reserves",
"terseLabel": "Raw materials"
}
}
},
"localname": "InventoryRawMaterialsNetOfReserves",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/InventoriesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InventoryWorkInProcessNetOfReserves": {
"auth_ref": [
"r30",
"r209"
],
"calculation": {
"http://www.westpharma.com/role/InventoriesDetails": {
"order": 2.0,
"parentTag": "us-gaap_InventoryNet",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
"label": "Inventory, Work in Process, Net of Reserves",
"terseLabel": "Work in process"
}
}
},
"localname": "InventoryWorkInProcessNetOfReserves",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/InventoriesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InvestmentIncomeNet": {
"auth_ref": [
"r85",
"r87"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
"order": 3.0,
"parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
"label": "Investment Income, Net",
"negatedTerseLabel": "Interest income"
}
}
},
"localname": "InvestmentIncomeNet",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
"auth_ref": [
"r15"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 4.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
"label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
"terseLabel": "Investments in affiliated companies"
}
}
},
"localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LeaseCost": {
"auth_ref": [
"r616",
"r618"
],
"calculation": {
"http://www.westpharma.com/role/LeasesLeaseCostDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lease cost recognized by lessee for lease contract.",
"label": "Lease, Cost",
"totalLabel": "Total lease cost"
}
}
},
"localname": "LeaseCost",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/LeasesLeaseCostDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LeaseCostTableTextBlock": {
"auth_ref": [
"r616"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
"label": "Lease, Cost [Table Text Block]",
"terseLabel": "Schedule of Lease, Cost"
}
}
},
"localname": "LeaseCostTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/LeasesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_LeasesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Leases [Abstract]",
"terseLabel": "Leases [Abstract]"
}
}
},
"localname": "LeasesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
"auth_ref": [
"r617"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
"label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
"terseLabel": "Schedule of Lessee, Operating Lease, Liability, Maturity"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/LeasesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
"auth_ref": [
"r617"
],
"calculation": {
"http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
},
"http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
"label": "Lessee, Operating Lease, Liability, to be Paid",
"totalLabel": "Operating leases liabilities payments due"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
"auth_ref": [
"r617"
],
"calculation": {
"http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
"order": 7.0,
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
"terseLabel": "Thereafter"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
"auth_ref": [
"r617"
],
"calculation": {
"http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
"order": 2.0,
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
"terseLabel": "Year one"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
"auth_ref": [
"r617"
],
"calculation": {
"http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
"order": 6.0,
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
"terseLabel": "Year five"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
"auth_ref": [
"r617"
],
"calculation": {
"http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
"order": 5.0,
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
"terseLabel": "Year four"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
"auth_ref": [
"r617"
],
"calculation": {
"http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
"order": 4.0,
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
"terseLabel": "Year three"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
"auth_ref": [
"r617"
],
"calculation": {
"http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
"order": 3.0,
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
"terseLabel": "Year two"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
"auth_ref": [
"r617"
],
"calculation": {
"http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
"order": 1.0,
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
"label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
"terseLabel": "Remainder of fiscal year"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
"auth_ref": [
"r617"
],
"calculation": {
"http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
"order": 1.0,
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
"label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
"negatedLabel": "Less: imputed lease interest"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeOperatingLeasesTextBlock": {
"auth_ref": [
"r619"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
"label": "Lessee, Operating Leases [Text Block]",
"terseLabel": "Leases"
}
}
},
"localname": "LesseeOperatingLeasesTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/Leases"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_LetterOfCreditMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
"label": "Letter of Credit [Member]",
"terseLabel": "Letter of Credit"
}
}
},
"localname": "LetterOfCreditMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_Liabilities": {
"auth_ref": [
"r41",
"r111",
"r180",
"r204",
"r253",
"r254",
"r255",
"r258",
"r259",
"r260",
"r262",
"r264",
"r266",
"r267",
"r520",
"r523",
"r524",
"r581",
"r626",
"r627"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 1.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
"label": "Liabilities",
"totalLabel": "Total Liabilities"
}
}
},
"localname": "Liabilities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesAndStockholdersEquity": {
"auth_ref": [
"r28",
"r111",
"r204",
"r581",
"r628",
"r650",
"r669"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
"label": "Liabilities and Equity",
"totalLabel": "Total Liabilities and Equity"
}
}
},
"localname": "LiabilitiesAndStockholdersEquity",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Liabilities and Equity [Abstract]",
"terseLabel": "LIABILITIES AND EQUITY"
}
}
},
"localname": "LiabilitiesAndStockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "stringItemType"
},
"us-gaap_LiabilitiesCurrent": {
"auth_ref": [
"r7",
"r43",
"r111",
"r204",
"r253",
"r254",
"r255",
"r258",
"r259",
"r260",
"r262",
"r264",
"r266",
"r267",
"r520",
"r523",
"r524",
"r581",
"r626",
"r627",
"r628"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 1.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
"label": "Liabilities, Current",
"totalLabel": "Total current liabilities"
}
}
},
"localname": "LiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesCurrentAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Liabilities, Current [Abstract]",
"terseLabel": "Current liabilities:"
}
}
},
"localname": "LiabilitiesCurrentAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "stringItemType"
},
"us-gaap_LiabilitiesFairValueDisclosure": {
"auth_ref": [
"r574"
],
"calculation": {
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value of financial and nonfinancial obligations.",
"label": "Liabilities, Fair Value Disclosure",
"totalLabel": "Total liabilities at fair value"
}
}
},
"localname": "LiabilitiesFairValueDisclosure",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesFairValueDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Liabilities, Fair Value Disclosure [Abstract]",
"terseLabel": "Liabilities:"
}
}
},
"localname": "LiabilitiesFairValueDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_LineOfCredit": {
"auth_ref": [
"r18",
"r649",
"r662"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
"label": "Long-Term Line of Credit",
"terseLabel": "Long-term line of credit"
}
}
},
"localname": "LineOfCredit",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": {
"auth_ref": [
"r39"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.",
"label": "Line of Credit Facility, Current Borrowing Capacity",
"terseLabel": "Line of credit facility, current borrowing capacity"
}
}
},
"localname": "LineOfCreditFacilityCurrentBorrowingCapacity",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LineOfCreditFacilityLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Line of Credit Facility [Line Items]",
"terseLabel": "Line of Credit Facility [Line Items]"
}
}
},
"localname": "LineOfCreditFacilityLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
"auth_ref": [
"r39"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
"label": "Line of Credit Facility, Remaining Borrowing Capacity",
"terseLabel": "Line of credit Facility, unused commitment level"
}
}
},
"localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LineOfCreditFacilityTable": {
"auth_ref": [
"r39",
"r110"
],
"lang": {
"en-us": {
"role": {
"documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
"label": "Line of Credit Facility [Table]",
"terseLabel": "Line of Credit Facility [Table]"
}
}
},
"localname": "LineOfCreditFacilityTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_LongMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicates an ownership position in, or purchase of, a security.",
"label": "Long [Member]",
"terseLabel": "Long"
}
}
},
"localname": "LongMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_LongTermDebt": {
"auth_ref": [
"r18",
"r282",
"r297",
"r298",
"r299",
"r649",
"r666"
],
"calculation": {
"http://www.westpharma.com/role/DebtLongtermDebtDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
},
"http://www.westpharma.com/role/DebtLongtermDebtDetails_1": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
"label": "Long-Term Debt",
"totalLabel": "Total debt"
}
}
},
"localname": "LongTermDebt",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DebtLongtermDebtDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtCurrent": {
"auth_ref": [
"r40"
],
"calculation": {
"http://www.westpharma.com/role/DebtLongtermDebtDetails": {
"order": 1.0,
"parentTag": "us-gaap_LongTermDebt",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
"label": "Long-Term Debt, Current Maturities",
"terseLabel": "Less: current portion of long-term debt"
}
}
},
"localname": "LongTermDebtCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DebtLongtermDebtDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtFairValue": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
"label": "Long-Term Debt, Fair Value",
"verboseLabel": "Long-term debt, fair value"
}
}
},
"localname": "LongTermDebtFairValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/FairValueMeasurementOtherFinancialInstrumentsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtNoncurrent": {
"auth_ref": [
"r18"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 2.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
},
"http://www.westpharma.com/role/DebtLongtermDebtDetails": {
"order": 2.0,
"parentTag": "us-gaap_LongTermDebt",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
"label": "Long-Term Debt, Excluding Current Maturities",
"terseLabel": "Long-term debt",
"verboseLabel": "Long-term debt, net"
}
}
},
"localname": "LongTermDebtNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED",
"http://www.westpharma.com/role/DebtLongtermDebtDetails",
"http://www.westpharma.com/role/DebtNarrativeDetails",
"http://www.westpharma.com/role/FairValueMeasurementOtherFinancialInstrumentsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongtermDebtTypeAxis": {
"auth_ref": [
"r45"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of long-term debt.",
"label": "Long-Term Debt, Type [Axis]",
"terseLabel": "Long-term Debt, Type [Axis]"
}
}
},
"localname": "LongtermDebtTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DebtLongtermDebtDetails",
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_LongtermDebtTypeDomain": {
"auth_ref": [
"r45",
"r252"
],
"lang": {
"en-us": {
"role": {
"documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
"label": "Long-Term Debt, Type [Domain]",
"terseLabel": "Long-term Debt, Type [Domain]"
}
}
},
"localname": "LongtermDebtTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DebtLongtermDebtDetails",
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_NetCashProvidedByUsedInFinancingActivities": {
"auth_ref": [
"r99"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
"order": 2.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
"label": "Net Cash Provided by (Used in) Financing Activities",
"totalLabel": "Net cash used in financing activities"
}
}
},
"localname": "NetCashProvidedByUsedInFinancingActivities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
"terseLabel": "Cash flows from financing activities:"
}
}
},
"localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetCashProvidedByUsedInInvestingActivities": {
"auth_ref": [
"r99"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
"order": 3.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
"label": "Net Cash Provided by (Used in) Investing Activities",
"totalLabel": "Net cash used in investing activities"
}
}
},
"localname": "NetCashProvidedByUsedInInvestingActivities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
"terseLabel": "Cash flows from investing activities:"
}
}
},
"localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetCashProvidedByUsedInOperatingActivities": {
"auth_ref": [
"r99",
"r100",
"r103"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
"order": 1.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
"label": "Net Cash Provided by (Used in) Operating Activities",
"totalLabel": "Net cash provided by operating activities"
}
}
},
"localname": "NetCashProvidedByUsedInOperatingActivities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
"terseLabel": "Cash flows from operating activities:"
}
}
},
"localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetIncomeLoss": {
"auth_ref": [
"r3",
"r65",
"r68",
"r73",
"r78",
"r103",
"r111",
"r121",
"r125",
"r126",
"r127",
"r128",
"r131",
"r132",
"r142",
"r173",
"r178",
"r181",
"r184",
"r187",
"r204",
"r253",
"r254",
"r255",
"r258",
"r259",
"r260",
"r262",
"r264",
"r266",
"r267",
"r569",
"r581",
"r654",
"r675"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
"order": 5.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
},
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
"order": 1.0,
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
"weight": 1.0
},
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
"label": "Net Income (Loss) Attributable to Parent",
"terseLabel": "Net income",
"totalLabel": "Net income",
"verboseLabel": "Total reclassifications for the period, net of tax"
}
}
},
"localname": "NetIncomeLoss",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails",
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED",
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
"http://www.westpharma.com/role/NetIncomePerShareSummaryofNetIncomePerShareDetails",
"http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetInvestmentHedgingMember": {
"auth_ref": [
"r532"
],
"lang": {
"en-us": {
"role": {
"documentation": "Hedges of a net investment in a foreign operation.",
"label": "Net Investment Hedging [Member]",
"terseLabel": "Net Investment Hedges:"
}
}
},
"localname": "NetInvestmentHedgingMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails",
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Accounting Standards Update and Change in Accounting Principle [Abstract]",
"terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]"
}
}
},
"localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
"auth_ref": [
"r1",
"r119",
"r120",
"r123",
"r124",
"r133",
"r134",
"r135",
"r199",
"r200",
"r207",
"r208",
"r503",
"r504",
"r505",
"r566",
"r570",
"r571",
"r572",
"r582",
"r583",
"r584",
"r604",
"r605",
"r620",
"r622",
"r642",
"r643",
"r644",
"r691",
"r692",
"r693",
"r694",
"r695"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
"label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
"verboseLabel": "New Accounting Standards"
}
}
},
"localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/NewAccountingStandards"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
"label": "New Accounting Pronouncements, Policy [Policy Text Block]",
"terseLabel": "New Accounting Standards"
}
}
},
"localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_NondesignatedMember": {
"auth_ref": [
"r533"
],
"lang": {
"en-us": {
"role": {
"documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
"label": "Not Designated as Hedging Instrument [Member]",
"terseLabel": "Not Designated as Hedging Instrument"
}
}
},
"localname": "NondesignatedMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails",
"http://www.westpharma.com/role/OtherIncomeExpenseOtherItemsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_NonoperatingIncomeExpense": {
"auth_ref": [
"r86"
],
"calculation": {
"http://www.westpharma.com/role/SegmentInformationDetails": {
"order": 1.0,
"parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
"label": "Nonoperating Income (Expense)",
"negatedTerseLabel": "Interest expense (income) and other nonoperating expense (income), net"
}
}
},
"localname": "NonoperatingIncomeExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/SegmentInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NumberOfReportableSegments": {
"auth_ref": [
"r161"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
"label": "Number of Reportable Segments",
"terseLabel": "Number of reportable segments"
}
}
},
"localname": "NumberOfReportableSegments",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/SegmentInformationDetails"
],
"xbrltype": "integerItemType"
},
"us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": {
"auth_ref": [
"r63",
"r74"
],
"calculation": {
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails": {
"order": 2.0,
"parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.",
"label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent",
"terseLabel": "Other comprehensive (loss) income before reclassifications"
}
}
},
"localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingIncomeLoss": {
"auth_ref": [
"r173",
"r178",
"r181",
"r184",
"r187"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
"order": 1.0,
"parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
"weight": 1.0
},
"http://www.westpharma.com/role/SegmentInformationDetails": {
"order": 2.0,
"parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The net result for the period of deducting operating expenses from operating revenues.",
"label": "Operating Income (Loss)",
"terseLabel": "Operating profit",
"totalLabel": "Operating profit"
}
}
},
"localname": "OperatingIncomeLoss",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
"http://www.westpharma.com/role/SegmentInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseCost": {
"auth_ref": [
"r609",
"r618"
],
"calculation": {
"http://www.westpharma.com/role/LeasesLeaseCostDetails": {
"order": 1.0,
"parentTag": "us-gaap_LeaseCost",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
"label": "Operating Lease, Cost",
"terseLabel": "Operating lease cost"
}
}
},
"localname": "OperatingLeaseCost",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/LeasesLeaseCostDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseLiability": {
"auth_ref": [
"r607"
],
"calculation": {
"http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
"order": 2.0,
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
"label": "Operating Lease, Liability",
"terseLabel": "Total lease liabilities"
}
}
},
"localname": "OperatingLeaseLiability",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseLiabilityCurrent": {
"auth_ref": [
"r607"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 1.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
"label": "Operating Lease, Liability, Current",
"terseLabel": "Operating lease liabilities"
}
}
},
"localname": "OperatingLeaseLiabilityCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseLiabilityNoncurrent": {
"auth_ref": [
"r607"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 5.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
"label": "Operating Lease, Liability, Noncurrent",
"terseLabel": "Operating lease liabilities"
}
}
},
"localname": "OperatingLeaseLiabilityNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeasePayments": {
"auth_ref": [
"r608",
"r612"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
"label": "Operating Lease, Payments",
"terseLabel": "Operating cash flows from operating leases"
}
}
},
"localname": "OperatingLeasePayments",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseRightOfUseAsset": {
"auth_ref": [
"r606"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 3.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's right to use underlying asset under operating lease.",
"label": "Operating Lease, Right-of-Use Asset",
"terseLabel": "Operating lease right-of-use assets"
}
}
},
"localname": "OperatingLeaseRightOfUseAsset",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
"auth_ref": [
"r615",
"r618"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average discount rate for operating lease calculated at point in time.",
"label": "Operating Lease, Weighted Average Discount Rate, Percent",
"terseLabel": "Weighted average discount rate"
}
}
},
"localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/LeasesLeaseWeightedAverageDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
"auth_ref": [
"r614",
"r618"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
"label": "Operating Lease, Weighted Average Remaining Lease Term",
"terseLabel": "Weighted average remaining lease term"
}
}
},
"localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/LeasesLeaseWeightedAverageDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_OperatingSegmentsMember": {
"auth_ref": [
"r177",
"r178",
"r179",
"r180",
"r181",
"r187"
],
"lang": {
"en-us": {
"role": {
"documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
"label": "Operating Segments [Member]",
"terseLabel": "Operating Segments"
}
}
},
"localname": "OperatingSegmentsMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/SegmentInformationDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_OptionMember": {
"auth_ref": [
"r525"
],
"lang": {
"en-us": {
"role": {
"documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received).",
"label": "Options Held [Member]",
"terseLabel": "Options Held"
}
}
},
"localname": "OptionMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_OtherAssetsCurrent": {
"auth_ref": [
"r36",
"r628"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 4.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of current assets classified as other.",
"label": "Other Assets, Current",
"terseLabel": "Other current assets"
}
}
},
"localname": "OtherAssetsCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherAssetsFairValueDisclosure": {
"auth_ref": [
],
"calculation": {
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": {
"order": 2.0,
"parentTag": "us-gaap_AssetsFairValueDisclosure",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value portion of other assets.",
"label": "Other Assets, Fair Value Disclosure",
"terseLabel": "Commodity call options"
}
}
},
"localname": "OtherAssetsFairValueDisclosure",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherAssetsNoncurrent": {
"auth_ref": [
"r14"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 9.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of noncurrent assets classified as other.",
"label": "Other Assets, Noncurrent",
"terseLabel": "Other noncurrent assets"
}
}
},
"localname": "OtherAssetsNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": {
"auth_ref": [
"r58",
"r60",
"r517",
"r521"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
"order": 1.0,
"parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.",
"label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent",
"negatedLabel": "Defined benefit pension and other postretirement plan adjustments, net of tax of $0.6, $0.0, $0.9, and $0.2, respectively"
}
}
},
"localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent": {
"auth_ref": [
"r517",
"r518",
"r521"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.",
"label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax, Attributable to Parent",
"terseLabel": "Defined benefit pension and other postretirement plan adjustments, tax"
}
}
},
"localname": "OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
"auth_ref": [
"r517",
"r518",
"r521"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
"order": 2.0,
"parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
"label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
"terseLabel": "Foreign currency translation adjustments, net of tax of $1.7, $0.3, $2.7 and $1.7, respectively"
}
}
},
"localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent": {
"auth_ref": [
"r517",
"r518",
"r521"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
"label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent",
"terseLabel": "Foreign currency translation adjustments, tax"
}
}
},
"localname": "OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
"auth_ref": [
"r54",
"r55",
"r60"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
"order": 4.0,
"parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
"label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
"terseLabel": "Net loss on equity affiliate accumulated other comprehensive income, net of tax of $0.0, $0.0, $0.0 and $0.0, respectively"
}
}
},
"localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax": {
"auth_ref": [
"r54",
"r55",
"r61"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
"label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax",
"terseLabel": "Net loss on equity affiliate accumulated other comprehensive income, tax"
}
}
},
"localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
"auth_ref": [
"r52",
"r60",
"r536",
"r540",
"r560"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
"label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
"terseLabel": "Cash flow hedges, amount of gain (loss) recognized in OCI"
}
}
},
"localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax": {
"auth_ref": [
"r544"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from discontinuance of cash flow hedge included in assessment of hedge effectiveness.",
"label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Reclassification for Discontinuance, before Tax",
"negatedTerseLabel": "Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income"
}
}
},
"localname": "OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsTax": {
"auth_ref": [
"r53",
"r60",
"r64"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of tax expense (benefit) for adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
"label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, Tax",
"terseLabel": "Net gain (loss) on derivatives, tax"
}
}
},
"localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax": {
"auth_ref": [
"r53",
"r541"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
"order": 3.0,
"parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
"label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax",
"terseLabel": "Net (loss) gain on derivatives, net of tax of $0.0, $0.8, $(0.8) and $0.0, respectively"
}
}
},
"localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
"auth_ref": [
"r547"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
"label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
"terseLabel": "Fair value and net investment hedges, amount of gain (loss) recognized in OCI"
}
}
},
"localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": {
"auth_ref": [
"r548"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.",
"label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax",
"negatedTerseLabel": "Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income"
}
}
},
"localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
"terseLabel": "Other comprehensive (loss) income, net of tax:"
}
}
},
"localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"
],
"xbrltype": "stringItemType"
},
"us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
"auth_ref": [
"r66",
"r69",
"r517",
"r518",
"r521"
],
"calculation": {
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
},
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
"order": 2.0,
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
"label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
"terseLabel": "Other comprehensive (loss) income, net of tax",
"totalLabel": "Other comprehensive (loss) income, net of tax"
}
}
},
"localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails",
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED",
"http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent": {
"auth_ref": [
],
"calculation": {
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": {
"order": 3.0,
"parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of the liabilities, classified as other, for deferred compensation arrangements payable after one year or the operating cycle, if longer.",
"label": "Other Deferred Compensation Arrangements, Liability, Classified, Noncurrent",
"terseLabel": "Deferred compensation liabilities"
}
}
},
"localname": "OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherIncome": {
"auth_ref": [
"r681"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of revenue and income classified as other.",
"label": "Other Income",
"terseLabel": "Other (income) expense"
}
}
},
"localname": "OtherIncome",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherIncomeAndExpensesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Other Income and Expenses [Abstract]",
"terseLabel": "Other Income and Expenses [Abstract]"
}
}
},
"localname": "OtherIncomeAndExpensesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
"auth_ref": [
"r358",
"r492"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.",
"label": "Other Income and Other Expense Disclosure [Text Block]",
"verboseLabel": "Other (Income) Expense"
}
}
},
"localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/OtherIncomeExpense"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_OtherLiabilitiesCurrent": {
"auth_ref": [
"r42",
"r628"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 7.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
"label": "Other Liabilities, Current",
"terseLabel": "Other current liabilities"
}
}
},
"localname": "OtherLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherLiabilitiesNoncurrent": {
"auth_ref": [
"r46"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 6.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
"label": "Other Liabilities, Noncurrent",
"terseLabel": "Other long-term liabilities"
}
}
},
"localname": "OtherLiabilitiesNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherNoncashIncomeExpense": {
"auth_ref": [
"r103"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
"order": 2.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
"label": "Other Noncash Income (Expense)",
"negatedLabel": "Other non-cash items, net"
}
}
},
"localname": "OtherNoncashIncomeExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherNonoperatingIncomeExpense": {
"auth_ref": [
"r88"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
"order": 4.0,
"parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
"label": "Other Nonoperating Income (Expense)",
"negatedLabel": "Other nonoperating (income) expense"
}
}
},
"localname": "OtherNonoperatingIncomeExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherOperatingIncomeExpenseNet": {
"auth_ref": [
],
"calculation": {
"http://www.westpharma.com/role/OtherIncomeExpenseSummaryDetails": {
"order": 2.0,
"parentTag": "wst_OtherIncomeExpense",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
"label": "Other Operating Income (Expense), Net",
"negatedTerseLabel": "Other items"
}
}
},
"localname": "OtherOperatingIncomeExpenseNet",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/OtherIncomeExpenseSummaryDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
"auth_ref": [
"r360",
"r361",
"r365",
"r366",
"r367",
"r368",
"r369",
"r370",
"r371",
"r372",
"r373",
"r374",
"r375",
"r376",
"r377",
"r378",
"r379",
"r380",
"r381",
"r382",
"r383",
"r384",
"r385",
"r386",
"r387",
"r389",
"r390",
"r391",
"r392",
"r393",
"r394",
"r396",
"r397",
"r398",
"r399",
"r400",
"r401",
"r402",
"r403",
"r404",
"r405",
"r406",
"r407",
"r408",
"r410",
"r411",
"r413",
"r416",
"r420",
"r425",
"r426",
"r427",
"r428",
"r429",
"r430",
"r431",
"r432",
"r433",
"r434",
"r435",
"r436",
"r439",
"r440",
"r441",
"r442",
"r443",
"r444"
],
"lang": {
"en-us": {
"role": {
"documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
"label": "Other Postretirement Benefits Plan [Member]",
"terseLabel": "Other retirement benefits"
}
}
},
"localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_OtherRestructuringMember": {
"auth_ref": [
"r234",
"r235",
"r241",
"r242"
],
"lang": {
"en-us": {
"role": {
"documentation": "Restructuring and related activities classified as other.",
"label": "Other Restructuring [Member]",
"terseLabel": "Other charges"
}
}
},
"localname": "OtherRestructuringMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/OtherIncomeExpenseRestructuringandRelatedChargesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities": {
"auth_ref": [
"r97"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
"order": 4.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
"label": "Payment for Contingent Consideration Liability, Operating Activities",
"negatedTerseLabel": "Contingent consideration payments in excess of acquisition-date liability"
}
}
},
"localname": "PaymentForContingentConsiderationLiabilityOperatingActivities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
"auth_ref": [
"r90",
"r92"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
"label": "Payments for (Proceeds from) Other Investing Activities",
"negatedLabel": "Other, net"
}
}
},
"localname": "PaymentsForProceedsFromOtherInvestingActivities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsForRepurchaseOfCommonStock": {
"auth_ref": [
"r94"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
"order": 2.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow to reacquire common stock during the period.",
"label": "Payments for Repurchase of Common Stock",
"negatedTerseLabel": "Shares purchased under share repurchase programs"
}
}
},
"localname": "PaymentsForRepurchaseOfCommonStock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsForRestructuring": {
"auth_ref": [
"r98",
"r235"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
"label": "Payments for Restructuring",
"negatedTerseLabel": "Cash payments"
}
}
},
"localname": "PaymentsForRestructuring",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/OtherIncomeExpenseRestructuringandRelatedChargesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsOfDebtIssuanceCosts": {
"auth_ref": [
"r96"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
"order": 7.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
"label": "Payments of Debt Issuance Costs",
"negatedTerseLabel": "Debt issuance costs"
}
}
},
"localname": "PaymentsOfDebtIssuanceCosts",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsOfDividendsCommonStock": {
"auth_ref": [
"r94"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.",
"label": "Payments of Ordinary Dividends, Common Stock",
"negatedLabel": "Dividend payments"
}
}
},
"localname": "PaymentsOfDividendsCommonStock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
"auth_ref": [
"r94"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
"order": 6.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
"label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
"negatedTerseLabel": "Shares repurchased for employee tax withholdings"
}
}
},
"localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
"auth_ref": [
"r91"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
"order": 2.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
"label": "Payments to Acquire Property, Plant, and Equipment",
"negatedLabel": "Capital expenditures"
}
}
},
"localname": "PaymentsToAcquirePropertyPlantAndEquipment",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
"auth_ref": [
"r386",
"r388",
"r394",
"r412",
"r414",
"r415",
"r416",
"r417",
"r418",
"r435",
"r437",
"r438",
"r439",
"r451"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for retirement benefits.",
"label": "Retirement Benefits [Text Block]",
"verboseLabel": "Benefit Plans"
}
}
},
"localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/BenefitPlans"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": {
"auth_ref": [
"r16",
"r361",
"r362",
"r385",
"r435"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 3.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.",
"label": "Liability, Defined Benefit Plan, Current",
"verboseLabel": "Pension and other postretirement benefits"
}
}
},
"localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": {
"auth_ref": [
"r19",
"r361",
"r362",
"r385",
"r435"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 4.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.",
"label": "Liability, Defined Benefit Plan, Noncurrent",
"terseLabel": "Pension and other postretirement benefits"
}
}
},
"localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PensionPlansDefinedBenefitMember": {
"auth_ref": [
"r359",
"r361",
"r365",
"r366",
"r367",
"r368",
"r369",
"r370",
"r371",
"r372",
"r373",
"r374",
"r375",
"r376",
"r377",
"r378",
"r379",
"r380",
"r381",
"r382",
"r383",
"r384",
"r385",
"r386",
"r387",
"r389",
"r390",
"r391",
"r392",
"r393",
"r394",
"r395",
"r396",
"r397",
"r398",
"r399",
"r400",
"r401",
"r402",
"r403",
"r404",
"r405",
"r406",
"r407",
"r408",
"r410",
"r411",
"r413",
"r416",
"r420",
"r425",
"r426",
"r427",
"r428",
"r429",
"r430",
"r431",
"r432",
"r433",
"r434",
"r435",
"r436",
"r439",
"r440",
"r446",
"r447",
"r448",
"r449"
],
"lang": {
"en-us": {
"role": {
"documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
"label": "Pension Plan [Member]",
"terseLabel": "Pension benefits"
}
}
},
"localname": "PensionPlansDefinedBenefitMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/BenefitPlansNarrativeDetails",
"http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_PerformanceSharesMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Share-based payment arrangement awarded for meeting performance target.",
"label": "Performance Shares [Member]",
"terseLabel": "Performance Share Unit (PSUs)"
}
}
},
"localname": "PerformanceSharesMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/StockBasedCompensationDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_PositionAxis": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by position taken for a security.",
"label": "Position [Axis]",
"terseLabel": "Position [Axis]"
}
}
},
"localname": "PositionAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_PositionDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicates position taken for a security.",
"label": "Position [Domain]",
"terseLabel": "Position [Domain]"
}
}
},
"localname": "PositionDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_PreferredStockSharesAuthorized": {
"auth_ref": [
"r21"
],
"lang": {
"en-us": {
"role": {
"documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
"label": "Preferred Stock, Shares Authorized",
"terseLabel": "Preferred stock, shares authorized (in shares)"
}
}
},
"localname": "PreferredStockSharesAuthorized",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockSharesIssued": {
"auth_ref": [
"r21",
"r306"
],
"lang": {
"en-us": {
"role": {
"documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
"label": "Preferred Stock, Shares Issued",
"terseLabel": "Preferred stock, shares issued (in shares)"
}
}
},
"localname": "PreferredStockSharesIssued",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockSharesOutstanding": {
"auth_ref": [
"r21"
],
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
"label": "Preferred Stock, Shares Outstanding",
"terseLabel": "Preferred stock, shares outstanding (in shares)"
}
}
},
"localname": "PreferredStockSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockValue": {
"auth_ref": [
"r21",
"r628"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 1.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
"label": "Preferred Stock, Value, Issued",
"terseLabel": "Preferred stock, 3.0\u00a0million shares authorized; 0 shares issued and outstanding"
}
}
},
"localname": "PreferredStockValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
"auth_ref": [
"r93",
"r487"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
"order": 4.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.",
"label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised",
"terseLabel": "Employee stock purchase plan contributions"
}
}
},
"localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromStockOptionsExercised": {
"auth_ref": [
"r93",
"r487"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
"order": 3.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
"label": "Proceeds from Stock Options Exercised",
"terseLabel": "Proceeds from stock-based compensation awards"
}
}
},
"localname": "ProceedsFromStockOptionsExercised",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProductConcentrationRiskMember": {
"auth_ref": [
"r156"
],
"lang": {
"en-us": {
"role": {
"documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
"label": "Product Concentration Risk [Member]",
"terseLabel": "Product Concentration Risk"
}
}
},
"localname": "ProductConcentrationRiskMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_PropertyPlantAndEquipmentGross": {
"auth_ref": [
"r11",
"r227"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 1.0,
"parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
"label": "Property, Plant and Equipment, Gross",
"terseLabel": "Property, plant and equipment"
}
}
},
"localname": "PropertyPlantAndEquipmentGross",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PropertyPlantAndEquipmentNet": {
"auth_ref": [
"r229",
"r628",
"r660",
"r670"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 2.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
"label": "Property, Plant and Equipment, Net",
"totalLabel": "Property, plant and equipment, net"
}
}
},
"localname": "PropertyPlantAndEquipmentNet",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]",
"terseLabel": "Reclassification out of Accumulated Other Comprehensive Loss [Line Items]"
}
}
},
"localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": {
"auth_ref": [
"r63",
"r74"
],
"calculation": {
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails": {
"order": 1.0,
"parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.",
"label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent",
"negatedLabel": "Amounts reclassified out from accumulated other comprehensive (loss) income"
}
}
},
"localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
"auth_ref": [
"r73"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
"label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
"terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
}
}
},
"localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
"auth_ref": [
"r73"
],
"lang": {
"en-us": {
"role": {
"documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
"label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
"terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
}
}
},
"localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
"auth_ref": [
"r73"
],
"lang": {
"en-us": {
"role": {
"documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
"label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
"terseLabel": "Reclassification out of Accumulated Other Comprehensive Loss"
}
}
},
"localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
"auth_ref": [
"r73"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
"label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
"terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
}
}
},
"localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
"label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]",
"terseLabel": "Schedule of Reclassification out of Accumulated Other Comprehensive Loss"
}
}
},
"localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
"auth_ref": [
"r178",
"r181"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
"label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
"terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]"
}
}
},
"localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/SegmentInformationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
"auth_ref": [
"r178",
"r181"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
"label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
"terseLabel": "Schedule of Segment Information"
}
}
},
"localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/SegmentInformationTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_RepaymentsOfNotesPayable": {
"auth_ref": [
"r95"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
"label": "Repayments of Notes Payable",
"terseLabel": "Repayment of notes"
}
}
},
"localname": "RepaymentsOfNotesPayable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RepaymentsOfOtherLongTermDebt": {
"auth_ref": [
"r95"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
"order": 5.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.",
"label": "Repayments of Other Long-Term Debt",
"negatedLabel": "Repayments of long-term debt"
}
}
},
"localname": "RepaymentsOfOtherLongTermDebt",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ResearchAndDevelopmentExpense": {
"auth_ref": [
"r493",
"r640",
"r712"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
"order": 1.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
"label": "Research and Development Expense",
"terseLabel": "Research and development"
}
}
},
"localname": "ResearchAndDevelopmentExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RestrictedStockUnitsRSUMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
"label": "Restricted Stock Units (RSUs) [Member]",
"terseLabel": "Restricted Stock Units (RSUs)"
}
}
},
"localname": "RestrictedStockUnitsRSUMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/StockBasedCompensationDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": {
"auth_ref": [
"r234",
"r237",
"r241",
"r243"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of costs incurred to date for the specified restructuring cost.",
"label": "Restructuring and Related Cost, Cost Incurred to Date",
"terseLabel": "Restructuring and related cost, cumulative cost incurred"
}
}
},
"localname": "RestructuringAndRelatedCostCostIncurredToDate1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/OtherIncomeExpenseNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RestructuringAndRelatedCostExpectedCost1": {
"auth_ref": [
"r234",
"r237",
"r241",
"r243"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
"label": "Restructuring and Related Cost, Expected Cost",
"terseLabel": "Restructuring and related cost, expected cost"
}
}
},
"localname": "RestructuringAndRelatedCostExpectedCost1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/OtherIncomeExpenseNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RestructuringAndRelatedCostIncurredCost": {
"auth_ref": [
"r234",
"r237",
"r241",
"r243"
],
"calculation": {
"http://www.westpharma.com/role/OtherIncomeExpenseSummaryDetails": {
"order": 1.0,
"parentTag": "wst_OtherIncomeExpense",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.",
"label": "Restructuring and Related Cost, Incurred Cost",
"terseLabel": "(Credits) charges",
"verboseLabel": "Restructuring and related charges"
}
}
},
"localname": "RestructuringAndRelatedCostIncurredCost",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/OtherIncomeExpenseRestructuringandRelatedChargesDetails",
"http://www.westpharma.com/role/OtherIncomeExpenseSummaryDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RestructuringCharges": {
"auth_ref": [
"r102",
"r233",
"r238",
"r241"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
"label": "Restructuring Charges",
"negatedTerseLabel": "Restructuring and severance related charges"
}
}
},
"localname": "RestructuringCharges",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/SegmentInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RestructuringCostAndReserveAxis": {
"auth_ref": [
"r234",
"r235",
"r241",
"r242"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of restructuring cost.",
"label": "Restructuring Type [Axis]",
"terseLabel": "Restructuring Type [Axis]"
}
}
},
"localname": "RestructuringCostAndReserveAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/OtherIncomeExpenseRestructuringandRelatedChargesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_RestructuringCostAndReserveLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Restructuring Cost and Reserve [Line Items]",
"terseLabel": "Restructuring Cost and Reserve [Line Items]"
}
}
},
"localname": "RestructuringCostAndReserveLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/OtherIncomeExpenseNarrativeDetails",
"http://www.westpharma.com/role/OtherIncomeExpenseRestructuringandRelatedChargesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_RestructuringPlanAxis": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by individual restructuring plan.",
"label": "Restructuring Plan [Axis]",
"terseLabel": "Restructuring Plan [Axis]"
}
}
},
"localname": "RestructuringPlanAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/OtherIncomeExpenseNarrativeDetails",
"http://www.westpharma.com/role/OtherIncomeExpenseRestructuringandRelatedChargesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_RestructuringPlanDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Identification of the individual restructuring plans.",
"label": "Restructuring Plan [Domain]",
"terseLabel": "Restructuring Plan [Domain]"
}
}
},
"localname": "RestructuringPlanDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/OtherIncomeExpenseNarrativeDetails",
"http://www.westpharma.com/role/OtherIncomeExpenseRestructuringandRelatedChargesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_RestructuringReserve": {
"auth_ref": [
"r235",
"r239"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
"label": "Restructuring Reserve",
"periodEndLabel": "Balance, June 30, 2022",
"periodStartLabel": "Balance, December 31, 2021"
}
}
},
"localname": "RestructuringReserve",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/OtherIncomeExpenseRestructuringandRelatedChargesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RestructuringReserveRollForward": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
"label": "Restructuring Reserve [Roll Forward]",
"terseLabel": "Restructuring Reserve [Roll Forward]"
}
}
},
"localname": "RestructuringReserveRollForward",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/OtherIncomeExpenseRestructuringandRelatedChargesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_RetainedEarningsAccumulatedDeficit": {
"auth_ref": [
"r24",
"r329",
"r628",
"r668",
"r691",
"r695"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 4.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
"label": "Retained Earnings (Accumulated Deficit)",
"verboseLabel": "Retained earnings"
}
}
},
"localname": "RetainedEarningsAccumulatedDeficit",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RetainedEarningsMember": {
"auth_ref": [
"r0",
"r116",
"r117",
"r118",
"r122",
"r130",
"r132",
"r206",
"r488",
"r489",
"r490",
"r501",
"r502",
"r567",
"r688",
"r690"
],
"lang": {
"en-us": {
"role": {
"documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
"label": "Retained Earnings [Member]",
"terseLabel": "Retained earnings"
}
}
},
"localname": "RetainedEarningsMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_RetirementPlanSponsorLocationAxis": {
"auth_ref": [
"r365",
"r366",
"r367",
"r368",
"r369",
"r370",
"r371",
"r372",
"r373",
"r374",
"r375",
"r376",
"r377",
"r378",
"r379",
"r380",
"r381",
"r382",
"r383",
"r384",
"r385",
"r386",
"r387",
"r389",
"r390",
"r391",
"r392",
"r393",
"r394",
"r395",
"r396",
"r397",
"r398",
"r399",
"r400",
"r401",
"r402",
"r403",
"r404",
"r405",
"r406",
"r407",
"r408",
"r409",
"r410",
"r411",
"r413",
"r416",
"r421",
"r422",
"r424",
"r425",
"r426",
"r427",
"r428",
"r429",
"r430",
"r431",
"r432",
"r433",
"r434",
"r440",
"r444",
"r449"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
"label": "Retirement Plan Sponsor Location [Axis]",
"terseLabel": "Retirement Plan Sponsor Location [Axis]"
}
}
},
"localname": "RetirementPlanSponsorLocationAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_RetirementPlanSponsorLocationDomain": {
"auth_ref": [
"r365",
"r366",
"r367",
"r368",
"r369",
"r370",
"r371",
"r372",
"r373",
"r374",
"r375",
"r376",
"r377",
"r378",
"r379",
"r380",
"r381",
"r382",
"r383",
"r384",
"r385",
"r386",
"r387",
"r389",
"r390",
"r391",
"r392",
"r393",
"r394",
"r395",
"r396",
"r397",
"r398",
"r399",
"r400",
"r401",
"r402",
"r403",
"r404",
"r405",
"r406",
"r407",
"r408",
"r409",
"r410",
"r411",
"r413",
"r416",
"r421",
"r422",
"r424",
"r425",
"r426",
"r427",
"r428",
"r429",
"r430",
"r431",
"r432",
"r433",
"r434",
"r440",
"r444",
"r449"
],
"lang": {
"en-us": {
"role": {
"documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
"label": "Retirement Plan Sponsor Location [Domain]",
"terseLabel": "Retirement Plan Sponsor Location [Domain]"
}
}
},
"localname": "RetirementPlanSponsorLocationDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_RetirementPlanTypeAxis": {
"auth_ref": [
"r359",
"r360",
"r361",
"r365",
"r366",
"r367",
"r368",
"r369",
"r370",
"r371",
"r372",
"r373",
"r374",
"r375",
"r376",
"r377",
"r378",
"r379",
"r380",
"r381",
"r382",
"r383",
"r384",
"r385",
"r386",
"r387",
"r389",
"r390",
"r391",
"r392",
"r393",
"r394",
"r395",
"r396",
"r397",
"r398",
"r399",
"r400",
"r401",
"r402",
"r403",
"r404",
"r405",
"r406",
"r407",
"r408",
"r410",
"r411",
"r413",
"r416",
"r420",
"r425",
"r426",
"r427",
"r428",
"r429",
"r430",
"r431",
"r432",
"r433",
"r434",
"r435",
"r436",
"r439",
"r440",
"r441",
"r442",
"r443",
"r444",
"r446",
"r447",
"r448",
"r449"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
"label": "Retirement Plan Type [Axis]",
"terseLabel": "Retirement Plan Type [Axis]"
}
}
},
"localname": "RetirementPlanTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/BenefitPlansNarrativeDetails",
"http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_RetirementPlanTypeDomain": {
"auth_ref": [
"r359",
"r360",
"r361",
"r365",
"r366",
"r367",
"r368",
"r369",
"r370",
"r371",
"r372",
"r373",
"r374",
"r375",
"r376",
"r377",
"r378",
"r379",
"r380",
"r381",
"r382",
"r383",
"r384",
"r385",
"r386",
"r387",
"r389",
"r390",
"r391",
"r392",
"r393",
"r394",
"r395",
"r396",
"r397",
"r398",
"r399",
"r400",
"r401",
"r402",
"r403",
"r404",
"r405",
"r406",
"r407",
"r408",
"r410",
"r411",
"r413",
"r416",
"r420",
"r425",
"r426",
"r427",
"r428",
"r429",
"r430",
"r431",
"r432",
"r433",
"r434",
"r435",
"r436",
"r439",
"r440",
"r441",
"r442",
"r443",
"r444",
"r446",
"r447",
"r448",
"r449"
],
"lang": {
"en-us": {
"role": {
"documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
"label": "Retirement Plan Type [Domain]",
"terseLabel": "Retirement Plan Type [Domain]"
}
}
},
"localname": "RetirementPlanTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/BenefitPlansNarrativeDetails",
"http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_RevenueFromContractWithCustomerAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Revenue from Contract with Customer [Abstract]",
"terseLabel": "Revenue from Contract with Customer [Abstract]"
}
}
},
"localname": "RevenueFromContractWithCustomerAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
"auth_ref": [
"r164",
"r165",
"r177",
"r182",
"r183",
"r190",
"r191",
"r194",
"r345",
"r346",
"r641"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
"order": 1.0,
"parentTag": "us-gaap_GrossProfit",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
"label": "Revenue from Contract with Customer, Excluding Assessed Tax",
"terseLabel": "Net sales"
}
}
},
"localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
"http://www.westpharma.com/role/SegmentInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RevenueFromContractWithCustomerTextBlock": {
"auth_ref": [
"r337",
"r338",
"r339",
"r340",
"r341",
"r342",
"r343",
"r344",
"r349",
"r357"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
"label": "Revenue from Contract with Customer [Text Block]",
"terseLabel": "Revenue"
}
}
},
"localname": "RevenueFromContractWithCustomerTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/Revenue"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_Revenues": {
"auth_ref": [
"r76",
"r111",
"r164",
"r165",
"r177",
"r182",
"r183",
"r190",
"r191",
"r194",
"r204",
"r253",
"r254",
"r255",
"r258",
"r259",
"r260",
"r262",
"r264",
"r266",
"r267",
"r581",
"r659"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
"label": "Revenues",
"verboseLabel": "Net sales"
}
}
},
"localname": "Revenues",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
"auth_ref": [
"r613",
"r618"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
"label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
"terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities"
}
}
},
"localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_SalesRevenueNetMember": {
"auth_ref": [
"r158",
"r194"
],
"lang": {
"en-us": {
"role": {
"documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
"label": "Revenue Benchmark [Member]",
"terseLabel": "Revenue Benchmark"
}
}
},
"localname": "SalesRevenueNetMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
"auth_ref": [
"r63",
"r595",
"r596"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
"label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
"terseLabel": "Schedule of Components of Accumulated Other Comprehensive Loss"
}
}
},
"localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfDebtTableTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
"label": "Schedule of Debt [Table Text Block]",
"terseLabel": "Schedule of Long-term Debt Obligations, Net of Current Maturities"
}
}
},
"localname": "ScheduleOfDebtTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DebtTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
"auth_ref": [
"r535",
"r545",
"r554"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
"label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
"terseLabel": "Schedule of Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and Earnings"
}
}
},
"localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": {
"auth_ref": [
"r526",
"r528",
"r529",
"r533",
"r534",
"r538",
"r545",
"r555",
"r556"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
"label": "Schedule of Derivative Instruments [Table Text Block]",
"terseLabel": "Schedule of Foreign Currency Contracts"
}
}
},
"localname": "ScheduleOfDerivativeInstrumentsTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
"auth_ref": [
"r145"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
"label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
"terseLabel": "Schedule of Reconciliation of Basic to Diluted Net Income Per Share"
}
}
},
"localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/NetIncomePerShareTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
"auth_ref": [
"r574",
"r575"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
"label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
"terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value"
}
}
},
"localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/FairValueMeasurementsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
"auth_ref": [
"r8",
"r32",
"r33",
"r34"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
"label": "Schedule of Inventory, Current [Table Text Block]",
"terseLabel": "Schedule of Inventories"
}
}
},
"localname": "ScheduleOfInventoryCurrentTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/InventoriesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
"auth_ref": [
"r398"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
"label": "Schedule of Net Benefit Costs [Table Text Block]",
"terseLabel": "Schedule of Components of Net Periodic Benefit Cost"
}
}
},
"localname": "ScheduleOfNetBenefitCostsTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/BenefitPlansTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
"auth_ref": [
"r543",
"r546"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.",
"label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]",
"terseLabel": "Schedule of Derivatives Not Designated as Hedging Instruments"
}
}
},
"localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
"auth_ref": [
"r234",
"r235",
"r236",
"r237",
"r241",
"r242",
"r243"
],
"lang": {
"en-us": {
"role": {
"documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
"label": "Schedule of Restructuring and Related Costs [Table]",
"terseLabel": "Schedule of Restructuring and Related Costs [Table]"
}
}
},
"localname": "ScheduleOfRestructuringAndRelatedCostsTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/OtherIncomeExpenseNarrativeDetails",
"http://www.westpharma.com/role/OtherIncomeExpenseRestructuringandRelatedChargesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
"auth_ref": [
"r235",
"r242"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
"label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
"terseLabel": "Schedule of Restructuring Reserve"
}
}
},
"localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/OtherIncomeExpenseTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
"auth_ref": [
"r452",
"r453",
"r456",
"r457",
"r458",
"r459",
"r460",
"r461",
"r462",
"r463",
"r464",
"r465",
"r466",
"r467",
"r468",
"r469",
"r470",
"r471",
"r472",
"r473",
"r474",
"r475",
"r476",
"r477",
"r478",
"r479",
"r480",
"r481"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about share-based payment arrangement.",
"label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
"terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
}
}
},
"localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/StockBasedCompensationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfStockByClassTable": {
"auth_ref": [
"r20",
"r21",
"r22",
"r108",
"r153",
"r154",
"r303",
"r304",
"r305",
"r306",
"r307",
"r308",
"r309",
"r311",
"r315",
"r320",
"r322",
"r323",
"r324",
"r325",
"r326",
"r327",
"r328",
"r329"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
"label": "Schedule of Stock by Class [Table]",
"terseLabel": "Schedule of Stock by Class [Table]"
}
}
},
"localname": "ScheduleOfStockByClassTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfStockholdersEquityTableTextBlock": {
"auth_ref": [
"r322"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.",
"label": "Schedule of Stockholders Equity [Table Text Block]",
"terseLabel": "Schedule of Stockholders Equity"
}
}
},
"localname": "ScheduleOfStockholdersEquityTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/ShareholdersEquityTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
"auth_ref": [
"r558"
],
"lang": {
"en-us": {
"role": {
"documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg.",
"label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
"terseLabel": "SOFR"
}
}
},
"localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_SegmentDomain": {
"auth_ref": [
"r160",
"r164",
"r165",
"r166",
"r167",
"r168",
"r169",
"r170",
"r171",
"r172",
"r173",
"r174",
"r175",
"r177",
"r178",
"r179",
"r180",
"r181",
"r182",
"r183",
"r184",
"r185",
"r187",
"r194",
"r212",
"r213",
"r214",
"r215",
"r216",
"r217",
"r218",
"r219",
"r220",
"r221",
"r237",
"r243",
"r682"
],
"lang": {
"en-us": {
"role": {
"documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
"label": "Segments [Domain]",
"terseLabel": "Segment [Domain]"
}
}
},
"localname": "SegmentDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/SegmentInformationDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_SegmentReportingAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Segment Reporting [Abstract]",
"terseLabel": "Segment Reporting [Abstract]"
}
}
},
"localname": "SegmentReportingAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_SegmentReportingDisclosureTextBlock": {
"auth_ref": [
"r160",
"r162",
"r163",
"r173",
"r176",
"r181",
"r185",
"r186",
"r187",
"r188",
"r190",
"r193",
"r194",
"r195"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
"label": "Segment Reporting Disclosure [Text Block]",
"verboseLabel": "Segment Information"
}
}
},
"localname": "SegmentReportingDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/SegmentInformation"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
"terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]"
}
}
},
"localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/SegmentInformationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_SellingGeneralAndAdministrativeExpense": {
"auth_ref": [
"r84"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
"order": 3.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
"label": "Selling, General and Administrative Expense",
"terseLabel": "Selling, general and administrative expenses"
}
}
},
"localname": "SellingGeneralAndAdministrativeExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ShareBasedCompensation": {
"auth_ref": [
"r101"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
"order": 3.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of noncash expense for share-based payment arrangement.",
"label": "Share-Based Payment Arrangement, Noncash Expense",
"negatedTerseLabel": "Stock-based compensation expense",
"terseLabel": "Stock-based compensation"
}
}
},
"localname": "ShareBasedCompensation",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
"http://www.westpharma.com/role/SegmentInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
"auth_ref": [
"r470"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
"terseLabel": "Granted (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/StockBasedCompensationDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
"auth_ref": [
"r470"
],
"lang": {
"en-us": {
"role": {
"documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
"terseLabel": "Grant date fair value (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/StockBasedCompensationDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
"auth_ref": [
"r479"
],
"lang": {
"en-us": {
"role": {
"documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
"terseLabel": "Dividend yield (in hundredths)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/StockBasedCompensationDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
"auth_ref": [
"r478"
],
"lang": {
"en-us": {
"role": {
"documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
"terseLabel": "Stock volatility (in hundredths)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/StockBasedCompensationDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
"auth_ref": [
"r480"
],
"lang": {
"en-us": {
"role": {
"documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
"terseLabel": "Risk-free interest rate (in hundredths)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/StockBasedCompensationDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
"terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/StockBasedCompensationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
"auth_ref": [
"r486"
],
"lang": {
"en-us": {
"role": {
"documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
"terseLabel": "Shares available for issuance under the 2016 Plan (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/StockBasedCompensationDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
"auth_ref": [
"r463"
],
"lang": {
"en-us": {
"role": {
"documentation": "Net number of share options (or share units) granted during the period.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
"terseLabel": "Stock options, granted (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/StockBasedCompensationDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
"auth_ref": [
"r473"
],
"lang": {
"en-us": {
"role": {
"documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
"terseLabel": "Stock options, weighted average grant date fair value (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/StockBasedCompensationDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
"auth_ref": [
"r456",
"r457",
"r458",
"r459",
"r460",
"r461",
"r462",
"r463",
"r464",
"r465",
"r466",
"r467",
"r468",
"r469",
"r470",
"r471",
"r472",
"r473",
"r474",
"r475",
"r476",
"r477",
"r478",
"r479",
"r480",
"r481"
],
"lang": {
"en-us": {
"role": {
"documentation": "Award under share-based payment arrangement.",
"label": "Award Type [Domain]",
"terseLabel": "Award Type [Domain]"
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/StockBasedCompensationDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
"auth_ref": [
"r463"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
"label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
"terseLabel": "Stock options, weighted average exercise price (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/StockBasedCompensationDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
"auth_ref": [
"r477"
],
"lang": {
"en-us": {
"role": {
"documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
"terseLabel": "Expected life (in years)"
}
}
},
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/StockBasedCompensationDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_ShortMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicates the sale of a borrowed security or written option.",
"label": "Short [Member]",
"terseLabel": "Short"
}
}
},
"localname": "ShortMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ShortTermLeaseCost": {
"auth_ref": [
"r610",
"r618"
],
"calculation": {
"http://www.westpharma.com/role/LeasesLeaseCostDetails": {
"order": 2.0,
"parentTag": "us-gaap_LeaseCost",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
"label": "Short-Term Lease, Cost",
"terseLabel": "Short-term lease cost"
}
}
},
"localname": "ShortTermLeaseCost",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/LeasesLeaseCostDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_SignificantAccountingPoliciesTextBlock": {
"auth_ref": [
"r106",
"r115"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
"label": "Significant Accounting Policies [Text Block]",
"verboseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
}
}
},
"localname": "SignificantAccountingPoliciesTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_StatementBusinessSegmentsAxis": {
"auth_ref": [
"r2",
"r160",
"r164",
"r165",
"r166",
"r167",
"r168",
"r169",
"r170",
"r171",
"r172",
"r173",
"r174",
"r175",
"r177",
"r178",
"r179",
"r180",
"r181",
"r182",
"r183",
"r184",
"r185",
"r187",
"r194",
"r212",
"r213",
"r214",
"r215",
"r216",
"r217",
"r218",
"r219",
"r220",
"r221",
"r231",
"r237",
"r243",
"r682"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by business segments.",
"label": "Segments [Axis]",
"terseLabel": "Segments [Axis]"
}
}
},
"localname": "StatementBusinessSegmentsAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/SegmentInformationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementEquityComponentsAxis": {
"auth_ref": [
"r0",
"r49",
"r71",
"r72",
"r73",
"r116",
"r117",
"r118",
"r122",
"r130",
"r132",
"r152",
"r206",
"r322",
"r329",
"r488",
"r489",
"r490",
"r501",
"r502",
"r567",
"r590",
"r591",
"r592",
"r593",
"r594",
"r596",
"r621",
"r688",
"r689",
"r690"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by component of equity.",
"label": "Equity Components [Axis]",
"terseLabel": "Equity Components [Axis]"
}
}
},
"localname": "StatementEquityComponentsAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails",
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails",
"http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfCashFlowsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Statement of Cash Flows [Abstract]",
"terseLabel": "Statement of Cash Flows [Abstract]"
}
}
},
"localname": "StatementOfCashFlowsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfFinancialPositionAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Statement of Financial Position [Abstract]"
}
}
},
"localname": "StatementOfFinancialPositionAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Statement of Comprehensive Income [Abstract]",
"terseLabel": "Statement of Comprehensive Income [Abstract]"
}
}
},
"localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
"auth_ref": [
"r21",
"r22",
"r322",
"r329"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
"label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
"terseLabel": "Activity related to stock -based compensation (in shares)"
}
}
},
"localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
"auth_ref": [
"r21",
"r22",
"r329",
"r473"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
"label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
"terseLabel": "Activity related to stock-based compensation"
}
}
},
"localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.",
"label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased",
"terseLabel": "Stock repurchase program, shares authorized (in shares)"
}
}
},
"localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/NetIncomePerShareNarrativeDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockholdersEquity": {
"auth_ref": [
"r22",
"r26",
"r27",
"r111",
"r198",
"r204",
"r581",
"r628"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 3.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
"label": "Stockholders' Equity Attributable to Parent",
"periodEndLabel": "Ending balance",
"periodStartLabel": "Beginning balance",
"totalLabel": "Total Equity"
}
}
},
"localname": "StockholdersEquity",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails",
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED",
"http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
"auth_ref": [
"r109",
"r307",
"r310",
"r311",
"r312",
"r313",
"r314",
"r315",
"r316",
"r317",
"r318",
"r319",
"r321",
"r329",
"r332",
"r565"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
"label": "Stockholders' Equity Note Disclosure [Text Block]",
"terseLabel": "Shareholders' Equity"
}
}
},
"localname": "StockholdersEquityNoteDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/ShareholdersEquity"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SubsequentEventMember": {
"auth_ref": [
"r597",
"r629"
],
"lang": {
"en-us": {
"role": {
"documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
"label": "Subsequent Event [Member]",
"terseLabel": "Subsequent Event"
}
}
},
"localname": "SubsequentEventMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_SubsequentEventTypeAxis": {
"auth_ref": [
"r597",
"r629"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
"label": "Subsequent Event Type [Axis]",
"terseLabel": "Subsequent Event Type [Axis]"
}
}
},
"localname": "SubsequentEventTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_SubsequentEventTypeDomain": {
"auth_ref": [
"r597",
"r629"
],
"lang": {
"en-us": {
"role": {
"documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
"label": "Subsequent Event Type [Domain]",
"terseLabel": "Subsequent Event Type [Domain]"
}
}
},
"localname": "SubsequentEventTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_TreasuryLockMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Customized agreement that fixes the yield or price on a specified treasury security for a specific period.",
"label": "Treasury Lock [Member]",
"terseLabel": "Forward treasury locks"
}
}
},
"localname": "TreasuryLockMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails",
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
"auth_ref": [
"r330"
],
"lang": {
"en-us": {
"role": {
"documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
"label": "Treasury Stock Acquired, Average Cost Per Share",
"terseLabel": "Stock repurchase program, average price per share (in dollars per share)"
}
}
},
"localname": "TreasuryStockAcquiredAverageCostPerShare",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/NetIncomePerShareNarrativeDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_TreasuryStockCommonMember": {
"auth_ref": [
"r330"
],
"lang": {
"en-us": {
"role": {
"documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.",
"label": "Treasury Stock, Common [Member]",
"terseLabel": "Treasury Stock"
}
}
},
"localname": "TreasuryStockCommonMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_TreasuryStockCommonShares": {
"auth_ref": [
"r330"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
"label": "Treasury Stock, Common, Shares",
"periodEndLabel": "Ending balance (in shares)",
"periodStartLabel": "Beginning balance (in shares)"
}
}
},
"localname": "TreasuryStockCommonShares",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_TreasuryStockShares": {
"auth_ref": [
"r48",
"r330"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
"label": "Treasury Stock, Shares",
"terseLabel": "Treasury stock, at cost (in shares)"
}
}
},
"localname": "TreasuryStockShares",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_TreasuryStockSharesAcquired": {
"auth_ref": [
"r22",
"r322",
"r329"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
"label": "Treasury Stock, Shares, Acquired",
"terseLabel": "Share purchased under share repurchase program (in shares)"
}
}
},
"localname": "TreasuryStockSharesAcquired",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/NetIncomePerShareNarrativeDetails",
"http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_TreasuryStockValue": {
"auth_ref": [
"r48",
"r330",
"r331"
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 6.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
"label": "Treasury Stock, Value",
"negatedTerseLabel": "Treasury stock, at cost (1.3\u00a0million and 1.1 million shares)"
}
}
},
"localname": "TreasuryStockValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_TreasuryStockValueAcquiredCostMethod": {
"auth_ref": [
"r322",
"r329",
"r330"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
"label": "Treasury Stock, Value, Acquired, Cost Method",
"negatedTerseLabel": "Shares purchased under share repurchase program",
"terseLabel": "Stock purchase program, cost of shares purchased"
}
}
},
"localname": "TreasuryStockValueAcquiredCostMethod",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/NetIncomePerShareNarrativeDetails",
"http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_TypeOfRestructuringDomain": {
"auth_ref": [
"r234",
"r235",
"r241",
"r242"
],
"lang": {
"en-us": {
"role": {
"documentation": "Identification of the types of restructuring costs.",
"label": "Type of Restructuring [Domain]",
"terseLabel": "Type of Restructuring [Domain]"
}
}
},
"localname": "TypeOfRestructuringDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/OtherIncomeExpenseRestructuringandRelatedChargesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_UnamortizedDebtIssuanceExpense": {
"auth_ref": [
],
"calculation": {
"http://www.westpharma.com/role/DebtLongtermDebtDetails_1": {
"order": 1.0,
"parentTag": "us-gaap_LongTermDebt",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.",
"label": "Unamortized Debt Issuance Expense",
"terseLabel": "Less: unamortized debt issuance costs"
}
}
},
"localname": "UnamortizedDebtIssuanceExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DebtLongtermDebtDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_VariableLeaseCost": {
"auth_ref": [
"r611",
"r618"
],
"calculation": {
"http://www.westpharma.com/role/LeasesLeaseCostDetails": {
"order": 3.0,
"parentTag": "us-gaap_LeaseCost",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
"label": "Variable Lease, Cost",
"terseLabel": "Variable lease cost"
}
}
},
"localname": "VariableLeaseCost",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/LeasesLeaseCostDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_VariableRateAxis": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of variable rate.",
"label": "Variable Rate [Axis]",
"terseLabel": "Variable Rate [Axis]"
}
}
},
"localname": "VariableRateAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_VariableRateDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
"label": "Variable Rate [Domain]",
"terseLabel": "Variable Rate [Domain]"
}
}
},
"localname": "VariableRateDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
"auth_ref": [
"r137",
"r145"
],
"calculation": {
"http://www.westpharma.com/role/NetIncomePerShareSummaryofNetIncomePerShareDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"lang": {
"en-us": {
"role": {
"documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
"label": "Weighted Average Number of Shares Outstanding, Diluted",
"terseLabel": "Diluted (in shares)",
"totalLabel": "Weighted average shares assuming dilution (in shares)"
}
}
},
"localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
"http://www.westpharma.com/role/NetIncomePerShareSummaryofNetIncomePerShareDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
"auth_ref": [
"r136",
"r145"
],
"calculation": {
"http://www.westpharma.com/role/NetIncomePerShareSummaryofNetIncomePerShareDetails": {
"order": 1.0,
"parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
"weight": 1.0
}
},
"lang": {
"en-us": {
"role": {
"documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
"label": "Weighted Average Number of Shares Outstanding, Basic",
"terseLabel": "Weighted average common shares outstanding (in shares)",
"verboseLabel": "Basic (in shares)"
}
}
},
"localname": "WeightedAverageNumberOfSharesOutstandingBasic",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
"http://www.westpharma.com/role/NetIncomePerShareSummaryofNetIncomePerShareDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
"verboseLabel": "Weighted average shares outstanding:"
}
}
},
"localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
],
"xbrltype": "stringItemType"
},
"wst_A2020RestructuringPlanMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "2020 Restructuring Plan [Member]",
"label": "2020 Restructuring Plan [Member]",
"terseLabel": "2020 Restructuring Plan"
}
}
},
"localname": "A2020RestructuringPlanMember",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/OtherIncomeExpenseNarrativeDetails",
"http://www.westpharma.com/role/OtherIncomeExpenseRestructuringandRelatedChargesDetails"
],
"xbrltype": "domainItemType"
},
"wst_AccruedSalariesWagesAndBenefitsCurrent": {
"auth_ref": [
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 5.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Accrued Salaries, Wages, and Benefits, Current",
"label": "Accrued Salaries, Wages, and Benefits, Current",
"terseLabel": "Accrued salaries, wages and benefits"
}
}
},
"localname": "AccruedSalariesWagesAndBenefitsCurrent",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"wst_ApplicableMarginMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Applicable Margin",
"label": "Applicable Margin [Member]",
"terseLabel": "Applicable Margin"
}
}
},
"localname": "ApplicableMarginMember",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"wst_BiologicsCustomersMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Biologics Customers [Member]",
"label": "Biologics Customers [Member]",
"terseLabel": "Biologics"
}
}
},
"localname": "BiologicsCustomersMember",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
],
"xbrltype": "domainItemType"
},
"wst_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Cash Paid For Amounts Included In The Measurement Of Lease Liabilities",
"label": "Cash Paid For Amounts Included In The Measurement Of Lease Liabilities [Abstract]",
"terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
}
}
},
"localname": "CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails"
],
"xbrltype": "stringItemType"
},
"wst_ContractManufacturedCustomersMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Contract-Manufactured Customers [Member]",
"label": "Contract-Manufactured Customers [Member]",
"terseLabel": "Contract-Manufactured Products"
}
}
},
"localname": "ContractManufacturedCustomersMember",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
],
"xbrltype": "domainItemType"
},
"wst_ContractManufacturedProductsMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Contract Manufactured Products [Member]",
"label": "Contract Manufactured Products [Member]",
"terseLabel": "Contract-Manufactured Products"
}
}
},
"localname": "ContractManufacturedProductsMember",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
],
"xbrltype": "domainItemType"
},
"wst_ContractWithCustomerAssetIncreaseDecrease": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Contract With Customer, Asset, Increase (Decrease)",
"label": "Contract With Customer, Asset, Increase (Decrease)",
"terseLabel": "Change in contract assets - increase (decrease)"
}
}
},
"localname": "ContractWithCustomerAssetIncreaseDecrease",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"wst_ContractWithCustomerAssetRollForward": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Contract With Customer, Asset [Roll Forward]",
"label": "Contract With Customer, Asset [Roll Forward]",
"terseLabel": "Contract With Customer, Asset [Roll Forward]"
}
}
},
"localname": "ContractWithCustomerAssetRollForward",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails"
],
"xbrltype": "stringItemType"
},
"wst_ContractWithCustomerLiabilityRollForward": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Contract With Customer, Liability [Roll Forward]",
"label": "Contract With Customer, Liability [Roll Forward]",
"terseLabel": "Contract With Customer, Liability [Roll Forward]"
}
}
},
"localname": "ContractWithCustomerLiabilityRollForward",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails"
],
"xbrltype": "stringItemType"
},
"wst_CostInvestmentImpairment": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Cost Investment Impairment",
"label": "Cost Investment Impairment",
"negatedTerseLabel": "Cost investment activity"
}
}
},
"localname": "CostInvestmentImpairment",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/SegmentInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"wst_CreditAvailableForTheIssuanceOfLettersOfCredit": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Credit Available For The Issuance Of Letters Of Credit",
"label": "Credit Available For The Issuance Of Letters Of Credit",
"terseLabel": "Credit available for the issuance of letters of credit"
}
}
},
"localname": "CreditAvailableForTheIssuanceOfLettersOfCredit",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"wst_CreditFacilityIsAvailableForSwingLineLoans": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Credit facility Is Available For Swing-Line Loans",
"label": "Credit facility Is Available For Swing-Line Loans",
"terseLabel": "Credit facility is available for swing-line loans"
}
}
},
"localname": "CreditFacilityIsAvailableForSwingLineLoans",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"wst_DebtInstrumentApplicableMarginRatio": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Debt Instrument, Applicable Margin Ratio",
"label": "Debt Instrument, Applicable Margin Ratio",
"terseLabel": "Applicable margin ratio"
}
}
},
"localname": "DebtInstrumentApplicableMarginRatio",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "pureItemType"
},
"wst_DebtInstrumentIncreaseInFacilityPrecedingPeriod": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Debt Instrument, Increase In Facility, Preceding Period",
"label": "Debt Instrument, Increase In Facility, Preceding Period",
"terseLabel": "Preceding period"
}
}
},
"localname": "DebtInstrumentIncreaseInFacilityPrecedingPeriod",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "durationItemType"
},
"wst_DebtInstrumentNumberOfFiscalQuartersFollowingAcquisition": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Debt Instrument, Number Of Fiscal Quarters Following Acquisition",
"label": "Debt Instrument, Number Of Fiscal Quarters Following Acquisition",
"terseLabel": "Number of quarters following acquisition"
}
}
},
"localname": "DebtInstrumentNumberOfFiscalQuartersFollowingAcquisition",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "integerItemType"
},
"wst_DebtInstrumentNumberOfInstancesRatioOfDebtToEBITDAExceeded": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Debt Instrument, Number Of Instances Ratio Of Debt To EBITDA Exceeded",
"label": "Debt Instrument, Number Of Instances Ratio Of Debt To EBITDA Exceeded",
"terseLabel": "Number of instances not to exceed"
}
}
},
"localname": "DebtInstrumentNumberOfInstancesRatioOfDebtToEBITDAExceeded",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "integerItemType"
},
"wst_DebtInstrumentRatioOfDebtToEBITDA": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Debt Instrument, Ratio Of Debt To EBITDA",
"label": "Debt Instrument, Ratio Of Debt To EBITDA",
"terseLabel": "Ratio of debt to EBITDA"
}
}
},
"localname": "DebtInstrumentRatioOfDebtToEBITDA",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "pureItemType"
},
"wst_DebtInstrumentRatioOfDebtToEBITDAAfterAcquisition": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Debt Instrument, Ratio Of Debt To EBITDA After Acquisition",
"label": "Debt Instrument, Ratio Of Debt To EBITDA After Acquisition",
"terseLabel": "Ratio of debt to EBITDA following acquisition"
}
}
},
"localname": "DebtInstrumentRatioOfDebtToEBITDAAfterAcquisition",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "pureItemType"
},
"wst_DeliveryDevicesMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Delivery Devices [Member]",
"label": "Delivery Devices [Member]",
"terseLabel": "Standard Packaging"
}
}
},
"localname": "DeliveryDevicesMember",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
],
"xbrltype": "domainItemType"
},
"wst_DeliverySystemsMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "A component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
"label": "Delivery Systems [Member]",
"terseLabel": "Contract-Manufactured Products"
}
}
},
"localname": "DeliverySystemsMember",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/SegmentInformationDetails"
],
"xbrltype": "domainItemType"
},
"wst_GenericsCustomersMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Generics Customers [Member]",
"label": "Generics Customers [Member]",
"terseLabel": "Generics"
}
}
},
"localname": "GenericsCustomersMember",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
],
"xbrltype": "domainItemType"
},
"wst_HighValueComponentsMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "High-Value Components [Member]",
"label": "High-Value Components [Member]",
"terseLabel": "High-Value Product Components"
}
}
},
"localname": "HighValueComponentsMember",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
],
"xbrltype": "domainItemType"
},
"wst_IntercompanyLoansMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Intercompany Loans",
"label": "Intercompany Loans [Member]",
"terseLabel": "Intercompany Loans"
}
}
},
"localname": "IntercompanyLoansMember",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"
],
"xbrltype": "domainItemType"
},
"wst_IntercompanyPayablesMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Intercompany Payables",
"label": "Intercompany Payables [Member]",
"terseLabel": "Intercompany Payables"
}
}
},
"localname": "IntercompanyPayablesMember",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"
],
"xbrltype": "domainItemType"
},
"wst_LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Lessee, Lease Cash Flow And Supplemental Information",
"label": "Lessee, Lease Cash Flow And Supplemental Information [Table Text Block]",
"terseLabel": "Schedule of Cash Flow and Supplemental Information"
}
}
},
"localname": "LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/LeasesTables"
],
"xbrltype": "textBlockItemType"
},
"wst_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
"auth_ref": [
],
"calculation": {
"http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
"order": 8.0,
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
"label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
"terseLabel": "Thereafter"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"wst_LineOfCreditFacilityAdditionalBorrowingCapacity": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Line Of Credit Facility Additional Borrowing Capacity",
"label": "Line Of Credit Facility Additional Borrowing Capacity",
"terseLabel": "Line of credit facility, additional borrowing capacity"
}
}
},
"localname": "LineOfCreditFacilityAdditionalBorrowingCapacity",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"wst_NetSalesMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Net sales member",
"label": "Net Sales [Member]",
"terseLabel": "Net sales"
}
}
},
"localname": "NetSalesMember",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"
],
"xbrltype": "domainItemType"
},
"wst_NotesPayableAndOtherDebtCurrent": {
"auth_ref": [
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"order": 2.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Notes Payable and Other Debt, Current",
"label": "Notes Payable and Other Debt, Current",
"verboseLabel": "Notes payable and other current debt"
}
}
},
"localname": "NotesPayableAndOtherDebtCurrent",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
],
"xbrltype": "monetaryItemType"
},
"wst_OtherFinancialInstrumentsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "-- None. No documentation exists for this element. --",
"label": "Other Financial Instruments [Abstract]",
"terseLabel": "Other Financial Instruments [Abstract]"
}
}
},
"localname": "OtherFinancialInstrumentsAbstract",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/FairValueMeasurementOtherFinancialInstrumentsDetails"
],
"xbrltype": "stringItemType"
},
"wst_OtherIncomeExpense": {
"auth_ref": [
],
"calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
"order": 4.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": 1.0
},
"http://www.westpharma.com/role/OtherIncomeExpenseSummaryDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The total amount of other income and expense items that are associated with the entity's normal revenue producing operation.",
"label": "Other Income (Expense)",
"negatedLabel": "Other (income) expense",
"negatedTotalLabel": "Total other (income) expense"
}
}
},
"localname": "OtherIncomeExpense",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
"http://www.westpharma.com/role/OtherIncomeExpenseSummaryDetails"
],
"xbrltype": "monetaryItemType"
},
"wst_PackagingSystemsMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "A component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
"label": "Packaging Systems [Member]",
"terseLabel": "Proprietary Products"
}
}
},
"localname": "PackagingSystemsMember",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/SegmentInformationDetails"
],
"xbrltype": "domainItemType"
},
"wst_PharmaCustomersMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Pharma Customers [Member]",
"label": "Pharma Customers [Member]",
"terseLabel": "Pharma"
}
}
},
"localname": "PharmaCustomersMember",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
],
"xbrltype": "domainItemType"
},
"wst_PurchasesAndRoyaltyPaymentsFromEquityMethodInvestees": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Purchases and Royalty Payments from Equity Method Investees",
"label": "Purchases and Royalty Payments from Equity Method Investees",
"terseLabel": "Purchases and royalty payments made to affiliates"
}
}
},
"localname": "PurchasesAndRoyaltyPaymentsFromEquityMethodInvestees",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/AffiliatedCompaniesDetails"
],
"xbrltype": "monetaryItemType"
},
"wst_PvsPayoutMaximum": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Percent of an employee's targeted award to be paid out, Maximum.",
"label": "PVS Payout Maximum",
"verboseLabel": "PSU payout, maximum (in hundredths)"
}
}
},
"localname": "PvsPayoutMaximum",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/StockBasedCompensationDetails"
],
"xbrltype": "percentItemType"
},
"wst_PvsPayoutMinimum": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Percent of an employee's targeted award to be paid out, Minimum.",
"label": "PVS Payout Minimum",
"verboseLabel": "PSU payout, minimum (in hundredths)"
}
}
},
"localname": "PvsPayoutMinimum",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/StockBasedCompensationDetails"
],
"xbrltype": "percentItemType"
},
"wst_RestructuringAndRelatedActivitiesPeriodOfImplementation": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Restructuring and Related Activities, Period of Implementation",
"label": "Restructuring and Related Activities, Period of Implementation",
"terseLabel": "Restructuring and related activities, period of implementation"
}
}
},
"localname": "RestructuringAndRelatedActivitiesPeriodOfImplementation",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/OtherIncomeExpenseNarrativeDetails"
],
"xbrltype": "durationItemType"
},
"wst_RevolvingCreditFacilityDue2024Member": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Revolving Credit Facility, Due 2024",
"label": "Revolving Credit Facility, Due 2024 [Member]",
"terseLabel": "Revolving credit facility, Due 2024"
}
}
},
"localname": "RevolvingCreditFacilityDue2024Member",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"wst_SalesToEquityMethodInvestees": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Sales to Equity Method Investees",
"label": "Sales to Equity Method Investees",
"terseLabel": "Sales to affiliates"
}
}
},
"localname": "SalesToEquityMethodInvestees",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/AffiliatedCompaniesDetails"
],
"xbrltype": "monetaryItemType"
},
"wst_ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule Of Other Income And Expense, By Component",
"label": "Schedule Of Other Income And Expense, By Component [Table Text Block]",
"terseLabel": "Schedule of Other (Income) Expense"
}
}
},
"localname": "ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/OtherIncomeExpenseTables"
],
"xbrltype": "textBlockItemType"
},
"wst_SeniorBNotesDue2024Member": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Senior B Notes Due 2024 [Member]",
"label": "Senior B Notes Due 2024 [Member]",
"terseLabel": "Series B notes, due July 5, 2024 (3.82%)"
}
}
},
"localname": "SeniorBNotesDue2024Member",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/DebtLongtermDebtDetails"
],
"xbrltype": "domainItemType"
},
"wst_SeniorCNotesDue2027Member": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Senior C Notes Due 2027 [Member]",
"label": "Senior C Notes Due 2027 [Member]",
"terseLabel": "Series C notes, due July 5, 2027 (4.02%)"
}
}
},
"localname": "SeniorCNotesDue2027Member",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/DebtLongtermDebtDetails"
],
"xbrltype": "domainItemType"
},
"wst_SeniorNotesDue2022Member": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Senior A Notes Due 2022 [Member]",
"label": "Senior A Notes Due 2022 [Member]",
"terseLabel": "Series A notes, due July 5, 2022 (3.67%)"
}
}
},
"localname": "SeniorNotesDue2022Member",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/DebtLongtermDebtDetails",
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"wst_SmartDoseMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "SmartDose [Member]",
"label": "SmartDose [Member]",
"terseLabel": "SmartDose"
}
}
},
"localname": "SmartDoseMember",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/RevenueNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"wst_StandardPackagingMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Standard Packaging [Member]",
"label": "Standard Packaging [Member]",
"terseLabel": "High-Value Product Delivery Devices"
}
}
},
"localname": "StandardPackagingMember",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
],
"xbrltype": "domainItemType"
},
"wst_TermLoanDue2024Member": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Term Loan Due 2024",
"label": "Term Loan Due 2024 [Member]",
"terseLabel": "Term Loan, due December 31, 2024 (3.03%)",
"verboseLabel": "Term Loan Due 2024"
}
}
},
"localname": "TermLoanDue2024Member",
"nsuri": "http://www.westpharma.com/20220630",
"presentation": [
"http://www.westpharma.com/role/DebtLongtermDebtDetails",
"http://www.westpharma.com/role/DebtNarrativeDetails"
],
"xbrltype": "domainItemType"
}
},
"unitCount": 12
}
},
"std_ref": {
"r0": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "105",
"URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
},
"r1": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "105",
"URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
},
"r10": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(10))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r100": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
},
"r101": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
},
"r102": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
},
"r103": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
},
"r104": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
},
"r105": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
},
"r106": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
},
"r107": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(c))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r108": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(d))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r109": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(e)(1))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r11": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(13))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r110": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(f))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r111": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(g)(1)(ii))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r112": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(h)(2))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r113": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(h))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r114": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.12-04(a))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
},
"r115": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "235",
"URI": "https://asc.fasb.org/topic&trid=2122369"
},
"r116": {
"Name": "Accounting Standards Codification",
"Paragraph": "23",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
},
"r117": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
},
"r118": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
},
"r119": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
},
"r12": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(14))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r120": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(1)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
},
"r121": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(2)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
},
"r122": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(3)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
},
"r123": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(4)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
},
"r124": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
},
"r125": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
},
"r126": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
},
"r127": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
},
"r128": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
},
"r129": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
},
"r13": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(15))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r130": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
},
"r131": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
},
"r132": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
},
"r133": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 11.M.Q2)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
},
"r134": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693"
},
"r135": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "250",
"URI": "https://asc.fasb.org/topic&trid=2122394"
},
"r136": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
},
"r137": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
},
"r138": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
},
"r139": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256"
},
"r14": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(17))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r140": {
"Name": "Accounting Standards Codification",
"Paragraph": "23",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256"
},
"r141": {
"Name": "Accounting Standards Codification",
"Paragraph": "28A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256"
},
"r142": {
"Name": "Accounting Standards Codification",
"Paragraph": "60B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
},
"r143": {
"Name": "Accounting Standards Codification",
"Paragraph": "60B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
},
"r144": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
},
"r145": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
},
"r146": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
},
"r147": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
},
"r148": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
},
"r149": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
},
"r15": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(18))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r150": {
"Name": "Accounting Standards Codification",
"Paragraph": "52",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
},
"r151": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "260",
"URI": "https://asc.fasb.org/topic&trid=2144383"
},
"r152": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "272",
"URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
},
"r153": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "272",
"URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
},
"r154": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "272",
"URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
},
"r155": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
},
"r156": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
},
"r157": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
},
"r158": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
},
"r159": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
},
"r16": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(20))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r160": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599"
},
"r161": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
},
"r162": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
},
"r163": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
},
"r164": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r165": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r166": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r167": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r168": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r169": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r17": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(21))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r170": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(g)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r171": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r172": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(j)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r173": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r174": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
},
"r175": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
},
"r176": {
"Name": "Accounting Standards Codification",
"Paragraph": "26",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599"
},
"r177": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
},
"r178": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
},
"r179": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
},
"r18": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(22))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r180": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
},
"r181": {
"Name": "Accounting Standards Codification",
"Paragraph": "31",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
},
"r182": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r183": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r184": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r185": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r186": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r187": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r188": {
"Name": "Accounting Standards Codification",
"Paragraph": "34",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599"
},
"r189": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599"
},
"r19": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(24))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r190": {
"Name": "Accounting Standards Codification",
"Paragraph": "40",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
},
"r191": {
"Name": "Accounting Standards Codification",
"Paragraph": "41",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
},
"r192": {
"Name": "Accounting Standards Codification",
"Paragraph": "41",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
},
"r193": {
"Name": "Accounting Standards Codification",
"Paragraph": "41",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
},
"r194": {
"Name": "Accounting Standards Codification",
"Paragraph": "42",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
},
"r195": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "280",
"URI": "https://asc.fasb.org/topic&trid=2134510"
},
"r196": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
},
"r197": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
},
"r198": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 4.E)",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
},
"r199": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "20",
"Subparagraph": "(d)(1)",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
},
"r2": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "205",
"URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
},
"r20": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(27)(b))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r200": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "20",
"Subparagraph": "(d)(2)",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
},
"r201": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "321",
"URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
},
"r202": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "321",
"URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714"
},
"r203": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "323",
"URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
},
"r204": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "323",
"URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
},
"r205": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "323",
"URI": "https://asc.fasb.org/topic&trid=2196965"
},
"r206": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
},
"r207": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)(1)",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
},
"r208": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)(2)",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
},
"r209": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 5.BB)",
"Topic": "330",
"URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
},
"r21": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(28))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r210": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "330",
"URI": "https://asc.fasb.org/topic&trid=2126998"
},
"r211": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
},
"r212": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r213": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r214": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r215": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r216": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(e)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r217": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(f)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r218": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r219": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(h)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r22": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(29))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r220": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r221": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
},
"r222": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
},
"r223": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
},
"r224": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "((a)(1),(b))",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r225": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)(2)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r226": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "360",
"URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
},
"r227": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "360",
"URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
},
"r228": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "360",
"URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
},
"r229": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "360",
"URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
},
"r23": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(1))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r230": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "360",
"URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
},
"r231": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "360",
"URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
},
"r232": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(c)",
"Topic": "410",
"URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
},
"r233": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "420",
"URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
},
"r234": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(1)",
"Topic": "420",
"URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
},
"r235": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(2)",
"Topic": "420",
"URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
},
"r236": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "420",
"URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
},
"r237": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "420",
"URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
},
"r238": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 5.P.3)",
"Topic": "420",
"URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
},
"r239": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
"Topic": "420",
"URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
},
"r24": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(3))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r240": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB TOPIC 5.P.4)",
"Topic": "420",
"URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
},
"r241": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 5.P.4(b)(1))",
"Topic": "420",
"URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
},
"r242": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 5.P.4(b)(2))",
"Topic": "420",
"URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
},
"r243": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 5.P.4(d))",
"Topic": "420",
"URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
},
"r244": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "440",
"URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
},
"r245": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "440",
"URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
},
"r246": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "440",
"URI": "https://asc.fasb.org/topic&trid=2144648"
},
"r247": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "450",
"URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
},
"r248": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "450",
"URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
},
"r249": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "20",
"Subparagraph": "(SAB Topic 5.Y.Q2)",
"Topic": "450",
"URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
},
"r25": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(4))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r250": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "20",
"Subparagraph": "(SAB Topic 5.Y.Q4)",
"Topic": "450",
"URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
},
"r251": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "450",
"URI": "https://asc.fasb.org/topic&trid=2127136"
},
"r252": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
},
"r253": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(i))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r254": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(ii))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r255": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r256": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r257": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iii))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r258": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iv))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r259": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(5))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r26": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r260": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(i))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r261": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r262": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r263": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r264": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r265": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r266": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iv))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r267": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(5))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r268": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r269": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r27": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(31))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r270": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r271": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r272": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(e)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r273": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(f)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r274": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r275": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(h)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r276": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(i)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r277": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r278": {
"Name": "Accounting Standards Codification",
"Paragraph": "1C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
},
"r279": {
"Name": "Accounting Standards Codification",
"Paragraph": "1C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
},
"r28": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(32))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r280": {
"Name": "Accounting Standards Codification",
"Paragraph": "1C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
},
"r281": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
},
"r282": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
},
"r283": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
},
"r284": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
},
"r285": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
},
"r286": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
},
"r287": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
},
"r288": {
"Name": "Accounting Standards Codification",
"Paragraph": "1F",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
},
"r289": {
"Name": "Accounting Standards Codification",
"Paragraph": "1F",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
},
"r29": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(a)(1))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r290": {
"Name": "Accounting Standards Codification",
"Paragraph": "1F",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(1)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
},
"r291": {
"Name": "Accounting Standards Codification",
"Paragraph": "1F",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(2)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
},
"r292": {
"Name": "Accounting Standards Codification",
"Paragraph": "1I",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
},
"r293": {
"Name": "Accounting Standards Codification",
"Paragraph": "1I",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
},
"r294": {
"Name": "Accounting Standards Codification",
"Paragraph": "1I",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
},
"r295": {
"Name": "Accounting Standards Codification",
"Paragraph": "1I",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
},
"r296": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(1)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
},
"r297": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(3)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
},
"r298": {
"Name": "Accounting Standards Codification",
"Paragraph": "69B",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
},
"r299": {
"Name": "Accounting Standards Codification",
"Paragraph": "69C",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
},
"r3": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "205",
"URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
},
"r30": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(a)(3))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r300": {
"Name": "Accounting Standards Codification",
"Paragraph": "69E",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
},
"r301": {
"Name": "Accounting Standards Codification",
"Paragraph": "69F",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
},
"r302": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "470",
"URI": "https://asc.fasb.org/topic&trid=2208564"
},
"r303": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(CFRR 211.02)",
"Topic": "480",
"URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
},
"r304": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
},
"r305": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644"
},
"r306": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r307": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r308": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r309": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r31": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(a)(4))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r310": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(g)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r311": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r312": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(i)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r313": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r314": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
},
"r315": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
},
"r316": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
},
"r317": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
},
"r318": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
},
"r319": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
},
"r32": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(a))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r320": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
},
"r321": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
},
"r322": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
},
"r323": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
},
"r324": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644"
},
"r325": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
},
"r326": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
},
"r327": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
},
"r328": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
},
"r329": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.3-04)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
},
"r33": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(b))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r330": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
},
"r331": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
},
"r332": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "505",
"URI": "https://asc.fasb.org/topic&trid=2208762"
},
"r333": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
},
"r334": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
},
"r335": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044"
},
"r336": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045"
},
"r337": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045"
},
"r338": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
},
"r339": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
},
"r34": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(c))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r340": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
},
"r341": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
},
"r342": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
},
"r343": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(2)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
},
"r344": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045"
},
"r345": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
},
"r346": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
},
"r347": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
},
"r348": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
},
"r349": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045"
},
"r35": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r350": {
"Name": "Accounting Standards Codification",
"Paragraph": "91",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
},
"r351": {
"Name": "Accounting Standards Codification",
"Paragraph": "91",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
},
"r352": {
"Name": "Accounting Standards Codification",
"Paragraph": "91",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
},
"r353": {
"Name": "Accounting Standards Codification",
"Paragraph": "91",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
},
"r354": {
"Name": "Accounting Standards Codification",
"Paragraph": "91",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
},
"r355": {
"Name": "Accounting Standards Codification",
"Paragraph": "91",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
},
"r356": {
"Name": "Accounting Standards Codification",
"Paragraph": "91",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Subparagraph": "(g)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
},
"r357": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "606",
"URI": "https://asc.fasb.org/topic&trid=49130388"
},
"r358": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "610",
"URI": "https://asc.fasb.org/topic&trid=49130413"
},
"r359": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "15",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "712",
"URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
},
"r36": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(8))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r360": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "15",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "712",
"URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
},
"r361": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919"
},
"r362": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919"
},
"r363": {
"Name": "Accounting Standards Codification",
"Paragraph": "3A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919"
},
"r364": {
"Name": "Accounting Standards Codification",
"Paragraph": "3A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919"
},
"r365": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r366": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(1)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r367": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(10)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r368": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(2)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r369": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(3)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r37": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(9))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r370": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(4)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r371": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(5)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r372": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(6)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r373": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(7)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r374": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(8)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r375": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(9)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r376": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r377": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(1)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r378": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(2)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r379": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(3)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r38": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19(a))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r380": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(4)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r381": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(5)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r382": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(6)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r383": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(7)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r384": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(8)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r385": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r386": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(i)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r387": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(ii)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r388": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iii)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r389": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(01)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r39": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19(b),22(b))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r390": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r391": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)(A)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r392": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)(B)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r393": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)(C)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r394": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(03)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r395": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(e)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r396": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(f)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r397": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r398": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(h)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r399": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(h)(1)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r4": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
},
"r40": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19,20)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r400": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(h)(2)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r401": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(h)(3)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r402": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(h)(4)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r403": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(h)(5)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r404": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(h)(6)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r405": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(h)(7)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r406": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(i)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r407": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(j)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r408": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(k)(1)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r409": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(k)(2)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r41": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19-26)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r410": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(k)(3)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r411": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(k)(4)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r412": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(l)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r413": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(n)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r414": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(o)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r415": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(p)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r416": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(q)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r417": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(r)(1)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r418": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(r)(2)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r419": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r42": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.20)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r420": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
},
"r421": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
},
"r422": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
},
"r423": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
},
"r424": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
},
"r425": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
},
"r426": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(1)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
},
"r427": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(2)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
},
"r428": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(3)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
},
"r429": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(4)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
},
"r43": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.21)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r430": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(5)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
},
"r431": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(6)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
},
"r432": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(7)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
},
"r433": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
},
"r434": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
},
"r435": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
},
"r436": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921"
},
"r437": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "20",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
},
"r438": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "60",
"Subparagraph": "(c)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
},
"r439": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "70",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
},
"r44": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.22(a)(1))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r440": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "35",
"SubTopic": "80",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
},
"r441": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Subparagraph": "(a)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
},
"r442": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Subparagraph": "(b)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
},
"r443": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Subparagraph": "(c)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
},
"r444": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
},
"r445": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Subparagraph": "(d)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
},
"r446": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Subparagraph": "(a)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
},
"r447": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Subparagraph": "(b)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
},
"r448": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Subparagraph": "(c)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
},
"r449": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Subparagraph": "(b)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
},
"r45": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.22)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r450": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "80",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
},
"r451": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "715",
"URI": "https://asc.fasb.org/topic&trid=2235017"
},
"r452": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "35",
"SubTopic": "10",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
},
"r453": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "35",
"SubTopic": "10",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
},
"r454": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900"
},
"r455": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r456": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r457": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r458": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(3)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r459": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r46": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.24)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r460": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(ii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r461": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r462": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r463": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(01)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r464": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(02)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r465": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(03)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r466": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(04)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r467": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r468": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(ii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r469": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r47": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.25)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r470": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)(01)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r471": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)(02)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r472": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)(03)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r473": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r474": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r475": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r476": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r477": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r478": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(ii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r479": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(iii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r48": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.29,30)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r480": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(iv)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r481": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(v)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r482": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)(1)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r483": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r484": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)(2)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r485": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(l)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r486": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r487": {
"Name": "Accounting Standards Codification",
"Paragraph": "2A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
},
"r488": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
},
"r489": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
},
"r49": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.29-31)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r490": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
},
"r491": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "718",
"URI": "https://asc.fasb.org/topic&trid=2228938"
},
"r492": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "720",
"URI": "https://asc.fasb.org/topic&trid=2122503"
},
"r493": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "730",
"URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
},
"r494": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
},
"r495": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
},
"r496": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
},
"r497": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
},
"r498": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
},
"r499": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
},
"r5": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
},
"r50": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
},
"r500": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
},
"r501": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)(2)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
},
"r502": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)(3)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
},
"r503": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)(1)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
},
"r504": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)(2)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
},
"r505": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)(3)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
},
"r506": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
},
"r507": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB TOPIC 6.I.7)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
},
"r508": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 11.C)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
},
"r509": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
},
"r51": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a),(b),(c)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
},
"r510": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "270",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
},
"r511": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
},
"r512": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "740",
"URI": "https://asc.fasb.org/topic&trid=2144680"
},
"r513": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "30",
"Topic": "805",
"URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
},
"r514": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "35",
"SubTopic": "30",
"Subparagraph": "(b)",
"Topic": "805",
"URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
},
"r515": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(c)(1)",
"Topic": "805",
"URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
},
"r516": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)(1)",
"Topic": "805",
"URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479"
},
"r517": {
"Name": "Accounting Standards Codification",
"Paragraph": "19",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
},
"r518": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
},
"r519": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
},
"r52": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
},
"r520": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
},
"r521": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(3)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
},
"r522": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c),(3)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
},
"r523": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bb)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
},
"r524": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
},
"r525": {
"Name": "Accounting Standards Codification",
"Paragraph": "83",
"Publisher": "FASB",
"Section": "15",
"SubTopic": "10",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126929950&loc=d3e34841-113949"
},
"r526": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
},
"r527": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
},
"r528": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
},
"r529": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
},
"r53": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(dd)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
},
"r530": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(1)(i)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
},
"r531": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(1)(ii)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
},
"r532": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(1)(iii)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
},
"r533": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
},
"r534": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
},
"r535": {
"Name": "Accounting Standards Codification",
"Paragraph": "4A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
},
"r536": {
"Name": "Accounting Standards Codification",
"Paragraph": "4A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(2)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
},
"r537": {
"Name": "Accounting Standards Codification",
"Paragraph": "4B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
},
"r538": {
"Name": "Accounting Standards Codification",
"Paragraph": "4B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
},
"r539": {
"Name": "Accounting Standards Codification",
"Paragraph": "4C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
},
"r54": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
},
"r540": {
"Name": "Accounting Standards Codification",
"Paragraph": "4C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
},
"r541": {
"Name": "Accounting Standards Codification",
"Paragraph": "4C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bb)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
},
"r542": {
"Name": "Accounting Standards Codification",
"Paragraph": "4C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
},
"r543": {
"Name": "Accounting Standards Codification",
"Paragraph": "4C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
},
"r544": {
"Name": "Accounting Standards Codification",
"Paragraph": "4C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
},
"r545": {
"Name": "Accounting Standards Codification",
"Paragraph": "4C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
},
"r546": {
"Name": "Accounting Standards Codification",
"Paragraph": "4CC",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959"
},
"r547": {
"Name": "Accounting Standards Codification",
"Paragraph": "4CCC",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
},
"r548": {
"Name": "Accounting Standards Codification",
"Paragraph": "4CCC",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
},
"r549": {
"Name": "Accounting Standards Codification",
"Paragraph": "4D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
},
"r55": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
},
"r550": {
"Name": "Accounting Standards Codification",
"Paragraph": "4D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(2)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
},
"r551": {
"Name": "Accounting Standards Codification",
"Paragraph": "4D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(6)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
},
"r552": {
"Name": "Accounting Standards Codification",
"Paragraph": "4D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
},
"r553": {
"Name": "Accounting Standards Codification",
"Paragraph": "4D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
},
"r554": {
"Name": "Accounting Standards Codification",
"Paragraph": "4E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
},
"r555": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959"
},
"r556": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
},
"r557": {
"Name": "Accounting Standards Codification",
"Paragraph": "182",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961"
},
"r558": {
"Name": "Accounting Standards Codification",
"Paragraph": "6A",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "20",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975"
},
"r559": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061172-113977"
},
"r56": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(h)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
},
"r560": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
},
"r561": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "25",
"Subparagraph": "(a)(1)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
},
"r562": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "25",
"Subparagraph": "(a)(2)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
},
"r563": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "25",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
},
"r564": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Subparagraph": "(f)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
},
"r565": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Subparagraph": "(a)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
},
"r566": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)(1)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
},
"r567": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)(3)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
},
"r568": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)(4)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
},
"r569": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
},
"r57": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(i),(j),(k)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
},
"r570": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(c)(1)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
},
"r571": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(c)(2)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
},
"r572": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(c)(3)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
},
"r573": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "815",
"URI": "https://asc.fasb.org/topic&trid=2229140"
},
"r574": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
},
"r575": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
},
"r576": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
},
"r577": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
},
"r578": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
},
"r579": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "825",
"URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
},
"r58": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(i-k)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
},
"r580": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "825",
"URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
},
"r581": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "825",
"URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
},
"r582": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)(1)",
"Topic": "825",
"URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
},
"r583": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)(2)",
"Topic": "825",
"URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
},
"r584": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)(3)",
"Topic": "825",
"URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
},
"r585": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885"
},
"r586": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "35",
"SubTopic": "20",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
},
"r587": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
},
"r588": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
},
"r589": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "230",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
},
"r59": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
},
"r590": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
},
"r591": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r592": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(b)",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r593": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(c)",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r594": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(d)",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r595": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r596": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
},
"r597": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
},
"r598": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "835",
"URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
},
"r599": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "835",
"URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
},
"r6": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
},
"r60": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
},
"r600": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "835",
"URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
},
"r601": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "835",
"URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
},
"r602": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "835",
"URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
},
"r603": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "30",
"Topic": "835",
"URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
},
"r604": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)(1)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
},
"r605": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)(3)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
},
"r606": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
},
"r607": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
},
"r608": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
},
"r609": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
},
"r61": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580"
},
"r610": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
},
"r611": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
},
"r612": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)(1)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
},
"r613": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)(2)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
},
"r614": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)(3)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
},
"r615": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)(4)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
},
"r616": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
},
"r617": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
},
"r618": {
"Name": "Accounting Standards Codification",
"Paragraph": "53",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
},
"r619": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"SubTopic": "20",
"Topic": "842",
"URI": "https://asc.fasb.org/subtopic&trid=77888251"
},
"r62": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
},
"r620": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)(1)",
"Topic": "848",
"URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846"
},
"r621": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(a)(3)(iii)(03)",
"Topic": "848",
"URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
},
"r622": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "848",
"URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
},
"r623": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "850",
"URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
},
"r624": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "850",
"URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
},
"r625": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "852",
"URI": "https://asc.fasb.org/extlink&oid=124433192&loc=d3e56071-112765"
},
"r626": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "852",
"URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
},
"r627": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "852",
"URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
},
"r628": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "852",
"URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
},
"r629": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "855",
"URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
},
"r63": {
"Name": "Accounting Standards Codification",
"Paragraph": "14A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
},
"r630": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(1)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r631": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(2)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r632": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r633": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(1)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r634": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(2)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r635": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r636": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(1)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r637": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(2)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r638": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r639": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "910",
"URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
},
"r64": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580"
},
"r640": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "730",
"Topic": "912",
"URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
},
"r641": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 11.L)",
"Topic": "924",
"URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
},
"r642": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "20",
"Subparagraph": "(f)(1)",
"Topic": "926",
"URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
},
"r643": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "20",
"Subparagraph": "(f)(2)",
"Topic": "926",
"URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
},
"r644": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "20",
"Subparagraph": "(f)(3)",
"Topic": "926",
"URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
},
"r645": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(10)(1))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r646": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(10))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r647": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(11))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r648": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(15)(1))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r649": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(16))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r65": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
},
"r650": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(23))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r651": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03.15(3))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r652": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03.17)",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r653": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(13)(f))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r654": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(22))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r655": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(23))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r656": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(26))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r657": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(27))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r658": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04.9)",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r659": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "235",
"Subparagraph": "(SX 210.9-05(b)(2))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
},
"r66": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
},
"r660": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "360",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
},
"r661": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "470",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
},
"r662": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(16))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r663": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(10))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r664": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(12))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r665": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r666": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(16))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r667": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r668": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r669": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(25))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r67": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
},
"r670": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(8))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r671": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03.(a),19)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r672": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03.17)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r673": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03.3)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r674": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(10))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r675": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(18))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r676": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(19))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r677": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(22))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r678": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(23))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r679": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(3)(d))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r68": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
},
"r680": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(9))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r681": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04.4)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r682": {
"Name": "Accounting Standards Codification",
"Paragraph": "4H",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
},
"r683": {
"Name": "Accounting Standards Codification",
"Paragraph": "7A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Subparagraph": "(d)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
},
"r684": {
"Name": "Accounting Standards Codification",
"Paragraph": "13H",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "40",
"Subparagraph": "(a)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
},
"r685": {
"Name": "Accounting Standards Codification",
"Paragraph": "13H",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "40",
"Subparagraph": "(b)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
},
"r686": {
"Name": "Accounting Standards Codification",
"Paragraph": "13H",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "40",
"Subparagraph": "(c)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
},
"r687": {
"Name": "Accounting Standards Codification",
"Paragraph": "29F",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "40",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
},
"r688": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r689": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)(1)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r69": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
},
"r690": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)(2)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r691": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(i)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r692": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(ii)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r693": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(iii)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r694": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(iv)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r695": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(h)(2)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r696": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "825",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
},
"r697": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04.12(3))",
"Topic": "946",
"URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
},
"r698": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "310",
"Subparagraph": "(SX 210.12-29(Footnote 4))",
"Topic": "948",
"URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
},
"r699": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "310",
"Topic": "954",
"URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594"
},
"r7": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
},
"r70": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
},
"r700": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "440",
"Subparagraph": "(a)",
"Topic": "954",
"URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
},
"r701": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column B))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r702": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column C))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r703": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column D))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r704": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column E))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r705": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column F))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r706": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column G))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r707": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column H))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r708": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column I))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r709": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Footnote 2))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r71": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
},
"r710": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "310",
"Subparagraph": "(c)",
"Topic": "976",
"URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
},
"r711": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "310",
"Subparagraph": "(b)",
"Topic": "978",
"URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
},
"r712": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "985",
"URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
},
"r713": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b"
},
"r714": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b-2"
},
"r715": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "d1-1"
},
"r716": {
"Name": "Form 10-Q",
"Number": "240",
"Publisher": "SEC",
"Section": "308",
"Subsection": "a"
},
"r717": {
"Name": "Forms 10-K, 10-Q, 20-F",
"Number": "240",
"Publisher": "SEC",
"Section": "13",
"Subsection": "a-1"
},
"r718": {
"Name": "Regulation S-T",
"Number": "232",
"Publisher": "SEC",
"Section": "405"
},
"r72": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
},
"r73": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
},
"r74": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
},
"r75": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(210.5-03(11))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r76": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(1))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r77": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(12))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r78": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(20))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r79": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(21))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r8": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
},
"r80": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(24))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r81": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(25))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r82": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.1,2)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r83": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.2(a),(d))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r84": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.4)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r85": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.7(a),(b))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r86": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.7)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r87": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.8)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r88": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.9)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r89": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "220",
"URI": "https://asc.fasb.org/topic&trid=2134417"
},
"r9": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(1))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r90": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
},
"r91": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
},
"r92": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
},
"r93": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
},
"r94": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
},
"r95": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
},
"r96": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
},
"r97": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(ee)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
},
"r98": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
},
"r99": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
}
},
"version": "2.1"
} |
